

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (4/98)  
Approved for use through 09/30/2000. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  <small>(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))</small>	Attorney Docket No. <b>1242/12/2</b>
	First Inventor or Application Identified <b>Thomas O. Daniel</b>
	Title <b>MODULATION OF ENDOTHELIAL CELL SURFACE...</b>
	Express Mail Label No. <b>EJ35368745IUS</b>

<b>APPLICATION ELEMENTS</b> See MPEP chapter 600 concerning utility patent application contents.	<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
1. <input checked="" type="checkbox"/> * Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original and a duplicate for fee processing)</small> 2. <input checked="" type="checkbox"/> Specification <span style="float: right;">[Total Pages] <b>125</b></span> <small>(preferred arrangement set forth below)</small> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) <span style="float: right;">[Total Sheets] <b>14</b></span> 4. Oath or Declaration <span style="float: right;">[Total Pages] <b>3</b></span> a. <input checked="" type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. § 1.63(d)) <small>(for continuation/divisional with Box 16 completed)</small> i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b). <b>* NOTE FOR ITEMS 1 &amp; 13 IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).</b>	5. <input type="checkbox"/> Microfiche Computer Program (Appendix) 6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies <b>ACCOMPANYING APPLICATION PARTS</b> 7. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 8. <input type="checkbox"/> 37 C.F.R. § 3.73(b) Statement <input type="checkbox"/> Power of Attorney <small>(when there is an assignee)</small> 9. <input type="checkbox"/> English Translation Document (if applicable) 10. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 11. <input type="checkbox"/> Preliminary Amendment 12. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small> 13. <input checked="" type="checkbox"/> * Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application <small>(PTO/SB/09-12)</small> Status still proper and desired 14. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small> 15. <input type="checkbox"/> Other:

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No: **09/152,160**  
 Prior application information: Examiner **Bansal, G.** Group / Art Unit: **1622**

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the continuing or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**17. CORRESPONDENCE ADDRESS**

☐ Customer Number or Bar Code Label or ☒ Correspondence address below  
(Insert Customer No. or Attach bar code label here)

Name	<b>Arles A. Taylor, Jr.</b>			
	<b>JENKINS &amp; WILSON, P.A.</b>			
Address	<b>Suite 1400 University Tower</b>			
	<b>3100 Tower Boulevard</b>			
City	<b>Durham</b>	State	<b>NC</b>	Zip Code <b>27707</b>
Country	<b>USA</b>	Telephone	<b>001-919-493-8000</b>	Fax <b>001-919-419-0383</b>

Name (Print/Type)	<b>Arles A. Taylor, Jr.</b>	Registration No. (Attorney/Agent)	<b>39,395</b>
Signature	<i>Arles A. Taylor, Jr.</i>	Date	<b>3/1/2000</b>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

JENKINS & WILSON, P.A.

PATENT ATTORNEYS  
SUITE 1400 UNIVERSITY TOWER  
3100 TOWER BOULEVARD  
DURHAM, NORTH CAROLINA 27707

TELEPHONE (919) 493-8000  
FACSIMILE (919) 419-0383

WEBSITE  
JENKINSANDWILSON.COM

PATENT, TRADEMARK  
AND COPYRIGHT  
PRACTICE

RALEIGH OFFICE  
NCSU CENTENNIAL CAMPUS  
VENTURE 11 SUITE 400  
920 MAIN CAMPUS DRIVE  
RALEIGH, NORTH CAROLINA 27608  
TELEPHONE (919) 424-3710  
FACSIMILE (919) 424-3711

RICHARD E. JENKINS  
JEFFREY L. WILSON

JENNIFER L. SKORD  
ARLES A. TAYLOR, JR.

DAVID P. GLOEKLER  
GREGORY A. HUNT

J. ERIK FAKO\* (PATENT AGENT)

\*ADMITTED ONLY IN MASSACHUSETTS

March 1, 2000

"Express Mail" mailing number: FJ35368745105  
Date of Deposit 03-01-00  
I hereby certify that this paper or fee is being deposited with the United States  
Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R.  
1.10 on the date indicated above and is addressed to the Commissioner of  
Patent and Trademarks, Washington, D.C.  
Lillian S. Glenn

*Lillian S. Glenn*

Assistant Commissioner for Patents  
BOX PATENT APPLICATION  
Washington, D.C. 20231

Re: U.S. Continuation Patent Application based  
on U.S. Patent Application Serial No. 09/152,160 for  
MODULATION OF ENDOTHELIAL CELL SURFACE RECEPTOR  
ACTIVITY IN THE REGULATION OF ANGIOGENESIS  
Our File No. 1242/12/2 CIP

Sir:

Please find enclosed the following:

1. A U.S. Continuation patent application for MODULATION OF ENDOTHELIAL CELL SURFACE RECEPTOR ACTIVITY IN THE REGULATION OF ANGIOGENESIS (125 pages);
2. Fourteen (14) sheets of informal drawings;
3. An unsigned Declaration (Form PTO/SB/01, 3 pages);
4. An unsigned Small Entity Statement (2 pages);
5. Utility Patent Application Transmittal Form (Form PTO/SB/05);
6. Fee Transmittal Form (Form PTO/SB/17);

Assistant Commissioner for Patents  
March 1, 2000  
Page 2

7. A check in the amount of \$674.00 to cover the small entity application filing fee;
8. A return-receipt postcard to be returned to our offices with the U.S. Patent and Trademark Office date stamp thereon; and
9. A Certificate of Express Mail No.: EJ353687451US.

Please contact our offices if there are any questions.

Respectfully submitted,

JENKINS & WILSON, P.A.



Arles A. Taylor, Jr.  
Registration No. 28,428

AAT/lsg

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Daniel, Thomas O.; Takahashi, Takamune; and Mernaugh, Raymond

Application No.:

Filed on:

Title: MODULATION OF ENDOTHELIAL CELL SURFACE...

**STATEMENT CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) and 1.27(b))--NONPROFIT ORGANIZATION**

I hereby state that I am an official empowered to act on behalf of the nonprofit organization identified below:

Name of Nonprofit : VANDERBILT UNIVERSITY  
Address of Nonprofit : 1207 17th Avenue South, Suite 210  
Nashville, TN 37212  
UNITED STATES OF AMERICA

**TYPE OF NONPROFIT ORGANIZATION**

University or Other Institution of Higher Education.

I hereby state that the nonprofit organization identified above qualifies as a nonprofit organization, as defined in 37 CFR 1.9(e), for purposes of paying reduced fees to the United States Patent and Trademark Office under Sections 41(a) and (b) of Title 35, United States Code, with regard to the invention described in the specification filed herewith, with title as listed above.

I hereby state that rights under contract or law have been conveyed to, and remain with, the nonprofit organization, with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. 1.9(c), if that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e)

No such person, concern, or organization exists. I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Janis Elsner  
Vanderbilt University  
1207 17th Avenue, Suite 210  
Nashville, TN 37212  
UNITED STATES OF AMERICA

SIGNATURE \_\_\_\_\_

Date \_\_\_\_\_

MODULATION OF ENDOTHELIAL CELL SURFACE RECEPTOR  
ACTIVITY IN THE REGULATION OF ANGIOGENESIS

AN APPLICATION FOR  
UNITED STATES LETTERS PATENT

By

Thomas O. Daniel  
Nashville, Tennessee

Takamune Takahashi  
Nashville, Tennessee

Raymond Mernaugh  
Nashville, Tennessee

-1- "Express Mail" mailing number EB5348745 US  
Date of Deposit 03-01-00  
I hereby certify that this paper or fee is being deposited with  
the United States Postal Service "Express Mail Post Office  
to Addressee" service under 37 C.F.R. 1.10 on the date  
indicated above and is addressed to the Commissioner of  
Patents and Trademarks, Washington, D.C. 20231  
Lillian S. Glenn

*Lillian S. Glenn*

### Description

## MODULATION OF ENDOTHELIAL CELL SURFACE RECEPTOR ACTIVITY IN THE REGULATION OF ANGIOGENESIS

### Cross Reference to Related Applications

- 5 This application is a continuation-in-part of co-pending U.S. Patent application serial number 09/152,160, filed September 10, 1998, herein incorporated by reference in its entirety.

### Grant Statement

- 10 This work was supported by NIH grants DK38517 and CA 68485. The U.S. Government has certain rights in the invention.

### Technical Field

- The present invention relates generally to the modulation of the activity of an endothelial cell surface receptor in the regulation of endothelial cell proliferation and migration and in the regulation of angiogenesis. More particularly, the present invention relates to the modulation of ECRT/DEP-1 activity in the regulation of endothelial cell proliferation and migration and in the regulation of angiogenesis.
- 15

### Background of the Invention

As used herein, the term "angiogenesis" means the generation of new blood vessels into a tissue or organ. Under normal physiological conditions, humans or animals undergo angiogenesis only in very specific restricted situations. For example, angiogenesis is normally observed in wound healing, fetal and embryonal development and formation of the corpus luteum, endometrium and placenta. The term "endothelium" means a thin layer of flat epithelial cells that lines serous cavities, lymph vessels, and blood vessels. The term "endothelial modulating activity" means the capability of a molecule to modulate angiogenesis in general and, for example, to stimulate or inhibit the growth of endothelial cells in culture. Both controlled and uncontrolled angiogenesis are thought to proceed in a similar manner. Endothelial cells and pericytes, surrounded by a basement membrane, form capillary blood vessels. Angiogenesis begins with the erosion of the basement membrane by enzymes released by endothelial cells and leukocytes. The endothelial cells, which line the lumen of blood vessels, then protrude through the basement membrane. Angiogenic stimulants induce the endothelial cells to migrate through the eroded basement membrane. The migrating cells form a "sprout" off the parent blood vessel, where the endothelial cells undergo mitosis and proliferate. The endothelial sprouts merge with each other to form capillary loops, creating the new blood vessel.

Persistent, unregulated angiogenesis occurs in a multiplicity of disease states, and abnormal growth by endothelial cells and supports the pathological damage seen in these conditions. The diverse pathological disease states in



which unregulated angiogenesis is present have been grouped together as angiogenic dependent or angiogenic associated diseases.

It is also recognized that angiogenesis plays a major role in the metastasis of a cancer. If this angiogenic activity could be repressed or eliminated, then the tumor, although present, would not grow. In the disease state, prevention of angiogenesis could avert the damage caused by the invasion of the new microvascular system. Therapies directed at control of the angiogenic processes could lead to the abrogation or mitigation of these diseases.

The development of renal glomerular capillaries is anatomically segregated and temporally staged in a multi-step process. The process involves recruitment of endothelial progenitors from adjacent mesenchyme, assembly of an arborized branching network, and maturation and specialization of endothelial cells adjacent to mesangial and visceral epithelial cells. Receptors for extracellular matrix components, cell surface molecules and growth factors have been assigned roles to mediate steps in this assembly process. See e.g., Wallner et al., *Microsc Res Tech* 39:261-284 (1997); Takahashi et al., *Kidney Int* 53:826-835 (1998).

Vascular endothelial growth factor (VEGF) is an important participant, as it is induced in S stage developing glomerular epithelial cells, and endothelial progenitors that are recruited to glomerular capillaries from the adjacent metanephric mesenchyme express the VEGF receptor, *flk-1*. Robert et al., *Am J Physiol* 271:F744-F753 (1996).

Neutralizing VEGF antibodies interrupt postnatal murine glomerular capillary development. Kitamoto et al., *J Clin Invest* 99:2351-2357 (1997).

Deletion of either PDGF $\beta$  receptor or PDGF $\beta$  genes in mice causes defective recruitment of mesangial cell precursors with failure of glomerular development.

- 5 Soriano, P., *Genes Dev* 8:1888-1896 (1994); Leveen et al., *Genes Dev* 8:1875-1887 (1994). TGF $\beta$ 1 expression and type II TGF $\beta$  receptors appear critical for vascular development in the embryonic yolk sac (prior to renal development), and type II receptors mediate *in vitro* capillary morphogenesis of endothelial cells derived from bovine glomeruli. Choime et al., *J Biol Chem* 270:21144-10 21150 (1995).

- Early evidence suggests that Eph family receptors and their ephrin ligands participate in glomerular vascular development. EphB1 receptors are expressed in isolated mesenchymal cells in a pattern similar to that of *flk-1*, and high level expression of ephrin-B1 is seen at the vascular cleft of developing glomeruli, as well as in capillary endothelial cells of mature glomeruli. Daniel 15 et al., *Kidney Int* 50:S-73-S-81 (1996). Oligomerized forms of ephrin-B1 stimulate in vitro assembly of human renal microvascular endothelial cells (HRMEC) into capillary-like structures. Stein et al., *Genes Dev* 12:667-678 (1998).

- 20 A selected subclass of receptor tyrosine phosphatases, including DPTP10D, serve important roles in directing axonal migration and neural network assembly. Desai et al., *Cell* 84:599-609 (1996). Recent data has identified mRNA expression of a related receptor phosphatase, ECRT/DEP-1, in arterial sites in mammalian kidney. Borges et al., *Circulation Research*

79:570-580 (1996). To date, however, there has been no evidence to implicate receptor tyrosine phosphatases in microvascular or glomerular capillary assembly or maturation.

Vascular endothelial cells display a diverse range of vascular bed specific properties (Gumkowski et al., *Blood Vessels* 24:11-13 (1987)), yet the requirement to maintain a continuous, antithrombotic monolayer lining the vascular space imposes rigorous requirements that their proliferation, migration and differentiation be regulated by interendothelial contacts. Specialized intercellular contacts permit communication among interacting endothelial cells (Lampugnani et al., *J Cell Biol* 129:203-217 (1995)) yet the mechanisms regulating arrest of proliferation and migration in response to interendothelial contact have not been elucidated. Tight regulatory control over proliferation imposed by interendothelial cell contact is apparent in the low basal mitotic index among endothelial cells in existing vessels. Engerman et al., *Laboratory Investigation* 17:738-744 (1967). This is in contrast with the proliferative endothelial responses that are evoked by mechanical disruption of large vessels. More et al., *J Pathol* 172:287-292 (1994). Similar proliferation and migration responses are stimulated at the margin of a confluent endothelial monolayer by "wounding", or physical removal cells from the packed monolayer. Coomber, *J Cell Biochem* 52:289-296 (1993).

The molecular basis for effects of interendothelial contact on migratory and proliferative responses is not defined, yet studies of cultured cells have shown that endothelial, fibroblast, and epithelial cells grow to confluency at a predictable density, then arrest proliferation (density arrest). Augenlicht and

Baserga, *Exp Cell Res* 89:255-262 (1974); Beekhuizen and van Furth, *J Vascular Res* 31:230-239 (1994); Rijksen et al., *J Cell Physiol* 154:393-401 (1993). This phenomenon can be very relevant to the behavior of endothelial cells in vascular sites in situ. Indeed, model culture systems of endothelial

5 "wounding" have shown that endothelial cells at the edge of an imposed "wound" rapidly extend lamellae, spread, migrate and proliferate to replace the deficit created by mechanical disruption of the monolayer. Coomber, *J Cell Biochem* 52:289-296 (1993).

Pallen and Tong observed that membrane-associated tyrosine

10 phosphatase activity recovered from cultured Swiss 3T3 cells increased eight (8)-fold (expressed as activity/mg protein) as cells approached a density of  $5 \times 10^4/\text{cm}^2$ , while soluble fraction tyrosine phosphatase was unaffected by cell density. Pallen and Tong, *Proc Natl Acad Sci USA* 88:6996-7000 (1991). Ostman et al. determined that the abundance of a receptor tyrosine

15 phosphatase cloned from HeLa cells and named DEP-1, is increased as cells approach high density. Ostman et al., *Proc Natl Acad Sci USA* 91:9680-9684 (1994). However, no links between molecules that evoke proliferation arrest and receptor tyrosine phosphatases have been made.

To date, available information does not indicate what sort of receptor-

20 ligand interaction might mediate a cell surface generated signal for density or contact arrest. The identification of such a receptor-ligand interaction is therefore needed in that it will serve as a basis for intervention in a disorder wherein density or contact arrest, or the preclusion of density or contact arrest, has therapeutic value. Such disorders include disorders characterized by

undesired angiogenesis, such as angiogenesis associated with tumor growth. Thus, what is also needed is a composition and method which can inhibit the unwanted growth of blood vessels, especially into tumors. The composition and method should attenuate the formation of the capillaries in the tumors thereby inhibiting the growth of the tumors.

### Summary of the Invention

In accordance with the present invention, a method of modulating angiogenesis in a vertebrate subject is provided. The method comprises administering to the vertebrate subject an EC RTP/DEP-1 activity modulating amount of a composition, whereby an EC RTP/DEP-1 within the vertebrate subject is contacted by the composition; and modulating angiogenesis through the contacting of the EC RTP/DEP-1 with the composition.

In accordance with the present invention a method of modulating endothelial cell migration and proliferation in a vertebrate subject is also provided. The method comprises administering to the vertebrate subject an EC RTP/DEP-1 activity-modulating amount of a composition, whereby an EC RTP/DEP-1 within the vertebrate subject is contacted by the composition; and modulating endothelial cell migration and proliferation through the contacting of the EC RTP/DEP-1 with the composition.

In accordance with the present invention there is also provided an antibody which preferentially binds the EC RTP/DEP-1. Optionally, the antibody comprises a monoclonal antibody or fragment or derivative thereof which preferentially binds the EC RTP/DEP-1.

In accordance with the present invention, a method for isolating an endogenous ligand for an EC RTP/DEP-1 is also provided. The method comprises the steps of contacting cells or cell lysates having the ligand with EC RTP/DEP-1; and isolating the ligand which binds with EC RTP/DEP-1.

5           A method of screening candidate substances for an ability to modulate EC RTP/DEP-1 biological activity is also disclosed. The method comprises establishing test samples comprising an EC RTP/DEP-1 polypeptide or fragment thereof; administering a candidate substance to the test samples; and measuring the interaction, effect, or combination thereof, of the candidate  
10           substance on the test sample to thereby determine the ability of the candidate substance to modulate EC RTP/DEP-1 biological activity.

          In accordance with the present invention there are also provided methods for performing a screening assay for identifying a compound that modulates an activity of an EC RTP/DEP-1 in both a cell-based and a cell-free  
15           assay. In a cell-based assay, the method comprises the steps of establishing replicate test and control cultures of cells that express the EC RTP/DEP-1; administering a candidate compound to the cells in the test culture but not the control culture; measuring EC RTP/DEP-1 activity in cells in the test and the control cultures; and determining that the candidate compound modulates the  
20           EC RTP/DEP-1 activity in a cell if the EC RTP/DEP-1 activity measured for the test culture is greater or less than the EC RTP/DEP-1 activity measured for the control culture.

          In a cell-free system, the method comprises the steps of establishing a control system comprising an EC RTP/DEP-1 and a ligand wherein the

ECRTP/DEP-1 is capable of binding to the ligand; establishing a test system comprising the ECRTP/DEP-1, the ligand, and a candidate compound; measuring the binding affinity of the ECRTP/DEP-1 and the ligand in the control and the test systems; and determining that the candidate compound  
5 modulates ECRTP/DEP-1 activity in a cell-free system if the binding affinity measured for the test system is less than or greater than the binding affinity measured for the control system.

In another embodiment, the screening assay methods of the present invention pertain to comparing the effect of a candidate compound to inhibit  
10 growth of cells expressing exogenous ECRTP/DEP-1 compared with those not expressing ECRTP/DEP-1 and determining that the effect of altering ECRTP/DEP-1 activity is responsible by demonstrating the lack of activity of the candidate compound on cells not expressing ECRTP/DEP-1. Thus, the screening assays of the present invention show changes in growth that are  
15 responsive to changes in ECRTP/DEP-1 activity.

In accordance with the present invention there is also provided a method for delivering a therapeutic composition to a tissue in a patient, wherein the tissue is characterized as having undesirable endothelial cell proliferation. The method comprises the steps of introducing into the patient a biologically  
20 effective amount of an antibody operatively linked to a selected therapeutic agent, the antibody preferentially binding to an ECRTP/DEP-1 on the surface of the endothelial cells, whereby an ECRTP/DEP-1 within the vertebrate subject is contacted by the antibody; and delivering the therapeutic composition to the tissue through the contacting of the ECRTP/DEP-1 with the composition.

It is therefore an object of the present invention to localize and characterize a receptor-ligand interaction which mediates a cell surface-generated signal for cell growth and survival.

It is another object of the present invention to provide for the modulation  
5 of a cell surface receptor activity in endothelial cells to mediate a cell surface-generated signal for cell growth and survival.

It is still another object of the present invention to provide for the modulation of a cell surface receptor activity for use in the inhibition or stimulation of angiogenesis.

10 It is yet another object of the present invention to identify compounds which modulate a receptor-ligand interaction which mediates a cell surface-generated signal for density or contact arrest.

Some of the aspects and objects of the invention having been stated  
hereinabove, other aspects and objects will become evident as the description  
15 proceeds, when taken in connection with the accompanying Drawings and Examples as best described hereinbelow.

#### Brief Description of the Drawings

Figure 1A depicts recognition by antibodies ECRTAb-1 & ECRTAb-2  
of recombinant and over-expressed EC RTP/DEP-1 and is an autoradiograph  
20 depicting recombinant proteins representing extracellular (Ec) or cytoplasmic (Cy) domains of EC RTP/DEP-1 were expressed in bacteria and purified. Proteins (100 ng) were separated on a 15% SDS-polyacrylamide gels,



transferred to PVDF membrane and probed with monoclonal antibodies ECRTAb-1 or ECRTAb-2, as indicated.

Figure 1B depicts recognition by antibodies ECRTAb-1 & ECRTAb-2 of recombinant and over-expressed ECRT/DEP-1 and is an autoradiograph depicting MDCK cells cultured in 100 mm dishes were transfected with 14 µg of empty pSRa vector (SRa) or pSRa-ECRT/DEP-1/HA (SRa-ECRT/HA) expression constructs and harvested at 48 hours after transfection. Membrane receptor proteins were recovered by WGA lectin-conjugated agarose from 150 µg of lysate protein. Lectin-adsorbed, eluted proteins were subjected to 7% SDS-PAGE, transferred to a PVDF membrane and probed with ECRTAb-1, ECRTAb-2, or anti-HA (HAAb) monoclonal antibodies, as indicated.

Figure 1C is a series of photographs depicting MDCK cells stably transfected with the pSRa-ECRT/DEP-1/HA plasmid were fixed with cold methanol and stained with ECRTAb-2 (panels a, c & d) or a class matched control antibody (panel b). ECRTAb-2 labeled lateral borders of cells in contact. Preincubation of ECRTAb-2 with 50 µg of recombinant immunogen (Ec) blocked this staining (panel c), while an irrelevant recombinant protein (Cy) did not (panel d).

Figures 2A-2E are a series of photographs depicting the abundance of ECRT/DEP-1 in endothelial cells of adult human kidney. Acetone fixed frozen sections (5 µm thickness) of human kidney were incubated with ECRTAb-1 (panels A-D) or a class matched control monoclonal antibody (panel E) and bound antibody was detected by epifluorescence microscopy, as described in Methods. ECRTAb-1 prominently labeled glomerular, peritubular and arterial

endothelial cells. Magnifications were A) x 100; B) x 600; C) x 600; D x 400; and E) x 100.

Figure 3 depicts confocal localization of EC RTP/DEP-1 and VE cadherin in human kidney vasculature. Acetone fixed kidney sections were simultaneously labeled with EC RTPAb-1 and a polyclonal goat antibody against VE cadherin. Bound antibodies were detected using fluorescein conjugated anti-mouse (panels A, B, E, F) or rhodamine-conjugated anti-goat (panels C, D, E, F) Ig antibodies. EC RTPAb-1 (green) staining distributed over the entire endothelial membrane in large artery and glomerular capillaries (A, B) while VE cadherin labeling (red) is restricted to endothelial junctions (C, D). Overlapping confocal images demonstrated colocalization of EC RTP with VE cadherin at inter-endothelial junctions. (magnification x 600).

Figure 4 is a series of photographs depicting EC RTP/DEP-1 expression in developing murine glomeruli. Cryostat kidney sections of embryonic day 14 (A), day 16 (B), postnatal day 6 (C) and adult mice (D) were immunolabeled with EC RTPAb-1 as described in the Methods of Example 1. In panels A & B; EC RTPAb-1 binds to cells dispersed in the mesenchymal area (arrow), to endothelial precursor cells (arrowhead) migrating to the vascular cleft of comma-shaped glomeruli and to endothelium of capillary stage glomeruli (G). In panels C & D, EC RTPAb-1 preferentially labels endothelial cells of the glomerulus (G), artery (A) and peritubular capillaries (arrow) in mature kidney. (Original magnification; A) x 400; B) x 200; C) x 200; and D) x 350.

Figure 5A depicts distribution of EC RTP/DEP-1 of inter-endothelial contacts in cultured human endothelial cells, but EC RTP/DEP-1 does not dissociate from junctions with VE cadherin and is a series of photographs depicting Methanol fixed HRMEC cells were labeled with EC RTPAb-2 as described in Methods of Example 1. EC RTP/DEP-1 is distributed between points of inter-endothelial membrane contact and punctate regions of the apical membrane in serial confocal images.

Figure 5B depicts distribution of EC RTP/DEP-1 of inter-endothelial contacts in cultured human endothelial cells, but EC RTP/DEP-1 does not dissociate from junctions with VE cadherin and is a series of photographs depicting HMEC-1 cells were grown to confluency, then incubated with media containing 5mM EGTA for 0 min (panels a & c) or 20 min (panels b & d), prior to fixation. The distribution of EC RTPAb-2 and VE cadherin labeling was examined as described in Methods of Example 1 at each time. While the distribution of EC RTP/DEP-1 immunoreactivity was not altered in the low  $\text{Ca}^{2+}$  medium, junctional VE cadherin staining dissipated, consistent with dissociation of VE cadherin junctions and redistribution across the cell membrane.

Figure 6A shows that endothelial cell density imposes growth arrest and increases lectin recoverable tyrosine phosphatase activity and is a line graph showing identical numbers of human renal microvascular endothelial cells (HRMEC) were plated in growth medium on 100 (1x), 60 (2.9x) or 35 (8.1x) mm diameter plastic dishes, effecting the indicated fold differences in cell density at the time of plating. Medium was replaced with growth medium at points indicated by arrows. Cells were counted in a Coulter counter and means of

quadruplicate samples are displayed. Proliferation was arrested in cells at 8.1x density after a single cell doubling, and after approximately 3 doublings in cells plated at 2.9x density.

Figure 6B shows that endothelial cell density imposes growth arrest and increases lectin recoverable tyrosine phosphatase activity and is a bar graph showing cells plated for the indicated times at the indicated densities were lysed, and receptor tyrosine phosphatase activity, including that attributable to EC RTP/DEP-1, was recovered by lectin affinity chromatography and assayed as described in Methods of Example 2 in the absence or presence of the tyrosine phosphatase inhibitor, sodium orthovanadate ( $\text{VO}_4$ , 100  $\mu\text{M}$ ).

Figure 7 is an autoradiograph and a bar graph showing that increased cell density imposes increases in activity, but not amount, of immunoprecipitated EC RTP/DEP-1. Identical numbers of HRMEC were plated as in Figure 6 at the indicated cell densities. Monospecific affinity purified rabbit polyclonal antibodies were used to immunoprecipitate EC RTP/DEP-1 from cells treated for 10 min immediately before harvest with 1mM peroxyvanadate ( $+\text{VO}_4$ ) or vehicle ( $-\text{VO}_4$ ) at 36 hours after plating, as described in Methods of Example 2. Recovered EC RTP/DEP-1 antigen was quantitated by immunoblot with the monospecific antibody and its endogenous phosphotyrosine content assessed by phosphotyrosine immunoblot using the 4G10 monoclonal antibody. Phosphatase activity in immunoprecipitated samples was assayed using pNPP as substrate in the absence ( $-\text{VO}_4$ ) or presence ( $\text{VO}_4$ ) of sodium orthovanadate, as described. Data are displayed as optical density of the product in triplicate samples  $\pm$  SEM.

Figure 8A shows that ECRT/DEP-1 overexpression, or bivalent antibody against ECRT/DEP-1, ECRTAb-1, imposes proliferation arrest on HRMEC and is a graph showing transient transfection of HRMEC with ECRT/DEP-1 cDNA imposes a growth inhibition at low cell densities.

- 5 Approximately  $3 \times 10^5$  HRMEC were cotransfected with 1.7 $\mu$ g pSR $\alpha$  (vector control) or HA epitope tagged (hemagglutinin) pSR $\alpha$ -ECRT/DEP-1 (pSR $\alpha$ -ECRT), as indicated, and 0.4 $\mu$ g pEGFP (Clontech) to permit scoring of BrdU labeling of transfected cells, as described in Methods of Example 2. At 24 hours, transfected cells were replated on p35 dishes in the numbers indicated.
- 10 Thirty six hours later, S phase cells were labeled for 30 min with BrdU, as described in Methods of Example 2, and +GFP positive cells were scored for BrdU incorporation. Data represent means  $\pm$  SEM for quadruplicate determinations.

- Figure 8B shows that ECRT/DEP-1 overexpression, or bivalent antibody against ECRT/DEP-1, ECRTAb-1, imposes proliferation arrest on HRMEC and is a line graph showing that ECRTAb-1 inhibits endothelial proliferation and migration. HRMEC ( $3 \times 10^4$ ) were plated in p35 dishes at time 0. Growth medium was replaced at 24h, cells were counted, and either IgG control (10 $\mu$ g/ml) or ECRTAb1 (10 $\mu$ g/ml) antibodies were added. Replicate
- 15 samples (5) of cells were counted on day 4, and are expressed as means  $\pm$  SEM.

Figure 8C is a data point plot depicting that equal numbers of HRMEC were plated at time 0, and antibodies or Fab fragments added at the concentrations indicated. Replicate plates were harvested on day 1, to confirm

homogeneous plating efficiency in each condition, and on day 6 to assess cell proliferation, respectively. Data points represent mean values of five replicates  $\pm$  SEM.

Figure 9A depicts inhibition of endothelial migration by ECRTAb-1 and is a series of photographs depicting monolayers of HRMEC were transiently transfected with plasmid pSR $\alpha$ ECRTP/DEP-1/HA, or pSR $\alpha$ EphB1/HA, as indicated. Forty eight hours later, "wounds" were created in the confluent monolayers and permitted to close over the ensuing 30 h. Monolayers were then stained with the monoclonal hemagglutinin antibody, 12CA5, to detect the positions of cells transiently expressing high levels of ECRTP/DEP-1/HA or EphB1/HA, respectively. Only rare ECRTP/DEP-1 overexpressing cells migrated to close the "wound".

Figure 9B depicts inhibition of endothelial migration by ECRTAb-1 and is a line graph reflecting analysis of 300 to 420  $\mu$ m diameter "wounds" which were created in HRMEC confluent monolayers at time 0, as medium was exchanged to serum-free medium supplemented by either no addition (NA), or phorbol myristate acetate (20ng/ml) in the presence of the indicated antibodies or fragments, including a class matched IgG control (IgG, 10 $\mu$ g/ml), ECRTAb1 (10 $\mu$ g/ml), or Fab fragments of ECRTAb1 (3 $\mu$ g/ml, molar equivalency). Triplicate wounds were used to generate microscopic images at the indicated times, and the residual "wound" area calculated and expressed as a fraction of the original wound, by an automated capture sequence using Bioquant Image Analysis Software. Each data point represents the mean  $\pm$  SEM of three determinations.

Figure 9C depicts inhibition of endothelial migration by ECRTAb-1 and is a line graph analyzing data produced by the same assay procedure as Figure 9B. Using the same assay procedure, migration rates were calculated by linear regression of mean values determined in cells exposed to IgG control, ECRTAb1, or ECRTAb1/Fab, using three independent time points.  $r^2$  values  $\geq 0.90$  for each data point plotted. The open square ( $\square$ ) indicates the migration rate for closure of unstimulated cells.

Figure 10 is line graph depicting that ECRTAb1 Fab fragments attenuate endothelial density mediated growth arrest. HMEC-1 cells of the indicated numbers were plated in on coverslips in 12 well dishes at time 0 in growth media supplemented by no addition (NA) or ECRTAb1 (67nM). Twenty four hours later BrdU staining was assayed as described in Methods of Example 2 and the percentage of BrdU positive cells scored by counting of five independent fields for each condition (greater than 400 cells/point). Data represent means  $\pm$  SEM.

Figure 11 is a series of photographs depicting that ECRTAb1 inhibits corneal pocket angiogenesis responses to bFGF. Hydrion pellets were impregnated with the angiogenesis stimulant, basic FGF (90ng), alone, or supplemented with a class matched control monoclonal antibody (IgG, 200ng) or ECRTAb1 (200ng), and placed in a pocket created in the corneal epithelium of anesthetized mice. Five days after implantation, angiogenic responses were scored, and photographed. Representative examples show inclusion of the ECRTAb1 inhibits the zone of proliferation around the implanted pellet.

Figure 12 is an autoradiograph showing that ECRTAb-1 binds peptide sequence QSRDTEVL of ECRT/DEP-1 ectodomain. A "peptides on paper" (Research Genetics Inc., Huntsville, Alabama) array was generated using the 351 amino acid sequence of ECRT which ECRTAb-1 binds. The array  
5 comprises 96 peptides of 8 - 10 amino acids spanning the entire region in overlapping sequences. A single peptide sequence (#41) in the series represents amino acid residues in n-QSRDTEVL-c.

Figure 13A is a combination of autoradiographs and a graph depicting that ECRTAb-1 promotes dephosphorylation of ECRT and arrests growth  
10 of transfected CHO cells expressing wild type ECRT, but not mutant ECRT proteins, C/S (catalytically inactivated point mutant) or cy (a cytoplasmic domain deletion). CHO cells were replated at 24 hours in the presence of ECRTAb-1, ECRTAb-1-Fab, or control IgG1 and assayed for cell number at 48 hours after transfection. In right panels, cells were transfected, cultured  
15 for 48 hours in serum-containing medium (5%), and exposed to 70nM of ECRTAb-1 or ECRTAb-1-Fab for the times indicated. ECRT was immunoprecipitated and assayed by immunoblot for phosphotyrosine content (anti-PY) and antigen recovery (anti-HA), as indicated. ECRTAb-1, but not ECRTAb-1-Fab, promoted acute dephosphorylation of wt but not catalytically  
20 inactive ECRT.

Figure 13B is a combination of autoradiographs and a graph demonstrating that cotransfection of wild type ECRT with either C/S or cy forms abrogates the dephosphorylation of ECRT imposed by exposure of cells to ECRTAb-1. These mutant forms function as dominant negative



proteins to block the ECRTpAb-1-induced formation of catalytically active ECRTp dimers that arrest cell growth and promote ECRTp dephosphorylation.

### Detailed Description of the Invention

A mammalian transmembrane protein gene product called DEP-1 (for  
5 density enhanced phosphatase), ECRTp, PTPRJ, HPTP $\eta$ , CD148, BYP,  
depending upon species and cDNA origin), was initially cloned from fibroblasts  
and was subsequently shown to be expressed (hereinafter referred to as an  
"ECRTp/DEP-1") on all hematopoietic lineages (de la Fuente-Garcia et al.,  
*Blood* 91:2800-2809 (1998), including erythroid progenitor cells,  
10 megakaryocytes and platelets, lymphocytes, polymorphonuclear leukocytes  
and platelets, and very prominently in endothelial cells. Borges et al.,  
*Circulation Research* 79:570-580 (1996), Schoecklmann et al., *J Am Soc  
Nephrol* 5:730 (1994)(abstract). This gene product has been shown to promote  
differentiation of erythroid progenitor cells (Kumet et al., *J Biol Chem*  
15 271:30916-30921 (1996)), to modulate lymphocyte function when crosslinked  
with other signaling proteins (de la Fuente-Garcia et al., *Blood* 91:2800-2809  
(1998)); and to inhibit clonal expression of breast cancer cell lines  
overexpressing the protein (Keane et al., *Cancer Research* 56:4236-4243  
(1996)).

20 In accordance with the present invention, it has been demonstrated that  
antibodies specific for ectodomain epitopes of the ECRTp/DEP-1 block  
endothelial migration and proliferation in response to phorbol myristate acetate  
and fetal bovine serum respectively. It is recognized that the biological activity

to inhibit endothelial proliferation and migration is a strong indicator of angiogenesis inhibitory activity. Accordingly, the EC RTP/DEP-1 is also a mediator of inhibitory signals that block angiogenesis.

In accordance with the present invention, then, antibodies that  
5 aggregate the EC RTP/DEP-1, including monoclonal antibody EC RTPAb-1 described herein, inhibit angiogenesis. Indeed, monoclonal antibodies against the ectodomain of EC RTP/DEP-1 inhibit proliferation (as demonstrated by BrdU uptake experiments) and migration of endothelial cells. Fab fragments of the same monoclonal have no such activity. Accordingly, such monoclonal  
10 EC RTP/DEP-1 antibodies described herein and derivatives thereof, have biological activity as angiogenesis inhibitors.

An endogenous ligand for the receptor ectodomain signals endothelial growth arrest. Therefore, in accordance with the present invention, a method of screening for the endogenous ligand is provided. For example, the  
15 endogenous ligand is isolated through the preparation of fusion proteins of the EC RTP/DEP-1 ectodomain as affinity reagents to identify, establish assays for, and clone the putative natural ligand expressed on endothelial cells. The purified and isolated endogenous ligand thus also has therapeutic application as an angiogenesis inhibitor.

20 In accordance with the present invention, synthetic peptides and peptidomimetics can also be used to contact the EC RTP/DEP-1 to activate EC RTP/DEP-1 activity.

The EC RTP/DEP-1 is expressed on the luminal and interendothelial membranes of endothelial cells in microvascular and large arterial vessels of

kidney and other organs, including but not limited to heart, spleen, muscle and skin. The EC RTP/DEP-1 localizes to interendothelial contacts in cultured endothelial cells, and in regions that overlap, but localization is not limited to the VE cadherin rich junctional complexes. EC RTP/DEP-1 activity (tyrosine phosphatase activity) increases approximately two times in confluent cells anticipating density mediated growth arrest. Moreover, over-expression of EC RTP/DEP-1 confers growth arrest on subconfluent endothelial cells. Thus, in accordance with the present invention, a method of modulating EC RTP/DEP-1 activity by contacting an EC RTP/DEP-1 with an EC RTP/DEP-1 modulating composition is contemplated. A method of screening for such a composition is also contemplated. Finally, a method of targeting a therapeutic composition to interendothelial contacts by preparing an antibody which preferably binds the EC RTP/DEP-1 and which is bound to the therapeutic composition is provided in accordance with the present invention.

15     A.     General Considerations

          The present invention relates generally to the discovery that angiogenesis is modulated by the EC RTP/DEP-1 and that activation of EC RTP/DEP-1 function inhibits angiogenesis. This discovery is important because of the role that angiogenesis plays in a variety of disease processes. By modulating angiogenesis, one can intervene in the disease, ameliorate the symptoms, and in some cases cure the disease.

          Where the growth of new blood vessels is the cause of, or contributes to, the pathology associated with a disease, inhibition of angiogenesis will

reduce the deleterious effects of the disease. Examples include rheumatoid arthritis, diabetic retinopathy, and the like. Where the growth of new blood vessels is required to support growth of a deleterious tissue, inhibition of angiogenesis will reduce the blood supply to the tissue and thereby contribute to reduction in tissue mass based on blood supply requirements. Examples include growth of tumors where neovascularization is a continual requirement in order that the tumor grow beyond a few millimeters in thickness, and for the establishment of solid tumor metastases.

The methods of the present invention are effective in part because the therapy is highly selective for angiogenesis and not other biological processes. As shown in the Examples, the EC RTP/DEP-1 localizes to endothelial cells and thus, primarily new vessel growth contains substantial EC RTP/DEP-1, and therefore the therapeutic methods do not adversely effect mature vessels. Furthermore, the EC RTP/DEP-1 is not widely distributed in normal tissues, but rather is found selectively on the surface of endothelial cells, thereby assuring that the therapy can be selectively targeted.

The discovery that binding the EC RTP/DEP-1 will effectively inhibit angiogenesis allows for the development of therapeutic compositions with potentially high specificity, and therefore relatively low toxicity. Thus although the invention discloses the preferred use of an anti-EC RTP/DEP-1 monoclonal antibody, one can design reagents which selectively bind EC RTP/DEP-1, and therefore do not have the side effect of modulating other biological processes other than those mediated by EC RTP/DEP-1.

As shown by the present teachings, it is possible to prepare monoclonal antibodies highly selective for immunoreaction with the EC RTP/DEP-1 that are similarly selective for modulation of EC RTP/DEP-1 function. In addition, peptides can be designed to be selective for binding to EC RTP/DEP-1, as described further herein. Prior to the discoveries of the present invention, it was not known that angiogenesis could be modulated in vivo by the use of reagents that modulate the biological function of EC RTP/DEP-1 or other receptor tyrosine phosphatase.

Other related methods are described in U.S. Patent Nos. 5,753,230; 5,733,876; 5,762,918; 5,776,427; 5,766,591; and 5,660,827, the entire contents of each of which are herein incorporated by reference.

Following long-standing patent law convention, the terms "a" and "an" mean "one or more" when used in this application, including the claims.

#### B. Methods For Modulating of Angiogenesis

The invention provides for a method for the modulation of angiogenesis in a tissue, and thereby modulating events in the tissue which depend upon angiogenesis. Generally, the method comprises administering to the tissue a composition comprising an angiogenesis-modulating amount of an EC RTP/DEP-1 modulator. As disclosed herein the term "modulate" is meant to encompass both the inhibition or stimulation of angiogenesis. Thus, the therapeutic methods of the present invention pertain to both the inhibition or stimulation of angiogenesis, depending on the disorder to be treated.

Angiogenesis includes a variety of processes involving neovascularization of a tissue including "sprouting", vasculogenesis, or vessel enlargement, all of which angiogenesis processes are mediated by and dependent upon the expression of ECRTF/DEP-1. With the exception of  
5 traumatic wound healing, corpus luteum formation and embryogenesis, it is believed that many angiogenesis processes are associated with disease processes.

There are a variety of diseases in which angiogenesis is believed to be important, referred to as angiogenic diseases, including but not limited to,  
10 inflammatory disorders such as immune and non-immune inflammation, chronic articular rheumatism and psoriasis, disorders associated with inappropriate or inopportune invasion of vessels such as diabetic retinopathy, neovascular glaucoma, capillary proliferation in atherosclerotic plaques and osteoporosis, and cancer associated disorders, such as solid tumors, solid  
15 tumor metastases, angiofibromas, retrolental fibroplasia, hemangiomas, Kaposi's sarcoma and the like cancers which require neovascularization to support tumor growth.

Thus, methods which inhibit angiogenesis in a diseased tissue ameliorates symptoms of the disease and, depending upon the disease, can  
20 contribute to cure of the disease. In one embodiment, the invention pertains to inhibition of angiogenesis, per se, in a tissue. The extent of angiogenesis in a tissue, and therefore the extent of inhibition achieved by the present methods, can be evaluated by a variety of methods, such as are described in

the Examples for detecting an ECRT/DEP-1-immunopositive immature and nascent vessel structures by immunohistochemistry.

As described herein, any of a variety of tissues, or organs comprised of organized tissues, can support angiogenesis in disease conditions including  
5 skin, muscle, gut, connective tissue, joints, bones and the like tissue in which blood vessels can invade upon angiogenic stimuli.

Thus, in one related embodiment, a tissue to be treated is an inflamed tissue and the angiogenesis to be inhibited is inflamed tissue angiogenesis where there is neovascularization of inflamed tissue. In this class the method  
10 contemplates inhibition of angiogenesis in arthritic tissues, such as in a patient with chronic articular rheumatism, in immune or non-immune inflamed tissues, in psoriatic tissue and the like.

The patient treated in the present invention in its many embodiments is desirably a human patient, although it is to be understood that the principles of  
15 the invention indicate that the invention is effective with respect to all vertebrate species, including mammals, which are intended to be included in the term "patient". In this context, a mammal is understood to include any mammalian species in which treatment of diseases associated with angiogenesis is desirable, particularly agricultural and domestic mammalian species.

20 The methods of the present invention are particularly useful in the treatment of warm-blooded vertebrates. Therefore, the invention concerns mammals and birds.

More particularly, contemplated is the treatment of mammals such as humans, as well as those mammals of importance due to being endangered

(such as Siberian tigers), of economical importance (animals raised on farms for consumption by humans) and/or social importance (animals kept as pets or in zoos) to humans, for instance, carnivores other than humans (such as cats and dogs), swine (pigs, hogs, and wild boars), ruminants (such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels), and horses. Also contemplated is the treatment of birds, including the treatment of those kinds of birds that are endangered, kept in zoos, as well as fowl, and more particularly domesticated fowl, i.e., poultry, such as turkeys, chickens, ducks, geese, guinea fowl, and the like, as they are also of economical importance to humans. Thus, contemplated is the treatment of livestock, including, but not limited to, domesticated swine (pigs and hogs), ruminants, horses, poultry, and the like.

In another related embodiment, a tissue to be treated is a retinal tissue of a patient with diabetic retinopathy, macular degeneration or neovascular glaucoma and the angiogenesis to be inhibited is retinal tissue angiogenesis where there is neovascularization of retinal tissue.

In an additional related embodiment, a tissue to be treated is a tumor tissue of a patient with a solid tumor, a metastases, a skin cancer, a hemangioma or angiofibroma and the like cancer, and the angiogenesis to be inhibited is tumor tissue angiogenesis where there is neovascularization of a tumor tissue.

Inhibition of tumor tissue angiogenesis is a particularly preferred embodiment because of the important role neovascularization plays in tumor growth. In the absence of neovascularization of tumor tissue, the tumor tissue



does not obtain the required nutrients, slows in growth, ceases additional growth, regresses and ultimately becomes necrotic resulting in killing of the tumor. Stated differently, the present invention provides for a method of modulating tumor neovascularization by modulating tumor angiogenesis according to the present methods. Similarly, the invention provides a method of modulating tumor growth by practicing the angiogenesis-modulating methods.

The methods are also particularly effective against the formation of metastases because (1) their formation requires vascularization of a primary tumor so that the metastatic cancer cells can exit the primary tumor and (2) their establishment in a secondary site requires neovascularization to support growth of the metastases.

In a related embodiment, the invention pertains to the practice of the method in conjunction with other therapies such as conventional chemotherapy or surgery directed against solid tumors and for control of establishment of metastases. The administration of angiogenesis inhibitor can be conducted before, during or after chemotherapy or surgery. For example, the angiogenesis inhibition methods of the present invention can be practiced for chronic maintenance. As additional example, the angiogenesis inhibition methods of the present invention can be practiced after a regimen of chemotherapy at times where the tumor tissue will be responding to the toxic assault by inducing angiogenesis to recover by the provision of a blood supply and nutrients to the tumor tissue. As a further example, the angiogenesis

inhibition methods of the present invention can be practiced after surgery where solid tumors have been removed as a prophylaxis against metastases.

The present method for modulating angiogenesis in a tissue contemplates contacting a tissue in which angiogenesis is occurring, or is at risk for occurring, with a composition comprising a therapeutically effective amount of an EC RTP/DEP-1 modulator capable of binding the EC RTP/DEP-1. Thus, the method comprises administering to a patient a therapeutically effective amount of a physiologically tolerable composition containing an EC RTP/DEP-1 modulator of the invention.

The dosage ranges for the administration of the EC RTP/DEP-1 modulator depend upon the form of the modulator, and its potency, as described further herein, and are amounts large enough to produce the desired effect in which angiogenesis and the disease symptoms mediated by angiogenesis are ameliorated. The dosage should not be so large as to cause adverse side effects, such as hyperviscosity syndromes, pulmonary edema, congestive heart failure, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage can also be adjusted by the individual physician in the event of any complication.

A therapeutically effective amount is an amount of an EC RTP/DEP-1 receptor modulator sufficient to produce a measurable inhibition of angiogenesis in the tissue being treated, i.e., an angiogenesis-modulating amount. Inhibition of angiogenesis can be measured in situ by

immunohistochemistry, as described herein, or by other methods known to one skilled in the art.

Insofar as an EC RTP/DEP-1 modulator can take the form of an EC RTP/DEP-1 ligand mimetic, and an anti-EC RTP/DEP-1 monoclonal antibody, or fragment thereof, it is to be appreciated that the potency, and therefore an expression of a "therapeutically effective" amount can vary. However, as shown by the present assay methods, one skilled in the art can readily assess the potency of a candidate EC RTP/DEP-1 modulator of the present invention.

EC RTP/DEP-1 modulator can be measured by a variety of means including inhibition of angiogenesis in the mouse corneal assay for angiogenesis described herein, binding of natural ligand or monoclonal antibody to an EC RTP/DEP-1 as described herein, and the like assays.

A preferred EC RTP/DEP-1 modulator has the ability to substantially bind to an EC RTP/DEP-1 in solution at modulator concentrations of less than one (1) micro molar ( $\mu\text{M}$ ), preferably less than 0.1  $\mu\text{M}$ , and more preferably less than 0.01  $\mu\text{M}$ . By "substantially" is meant that at least a 50 percent reduction in endothelial cell proliferation and migration is observed by modulation in the presence of the an EC RTP/DEP-1 modulator, and at 50% reduction is referred to herein as an IC50 value.

A therapeutically effective amount of an EC RTP/DEP-1 modulator of the present invention in the form of a monoclonal antibody, or fragment thereof, is typically an amount such that when administered in a physiologically tolerable composition is sufficient to achieve a plasma concentration of from about 0.01

microgram ( $\mu\text{g}$ ) per milliliter ( $\text{mL}$ ) to about  $100 \mu\text{g/mL}$ , preferably from about  $1 \mu\text{g/mL}$  to about  $5 \mu\text{g/mL}$ , and usually about  $5 \mu\text{g/mL}$ . For example, for Mab EC RTP/DEP-1 ( $\text{MW} = \text{about } 150\text{kDa}$ ),  $10 \mu\text{g/mL} \approx 67 \times 10^{-9} \text{ M}$ . Stated differently, the dosage can vary from about  $0.1 \text{ mg/kg}$  to about  $300 \text{ mg/kg}$ ,  
5 preferably from about  $0.2 \text{ mg/kg}$  to about  $200 \text{ mg/kg}$ , most preferably from about  $0.5 \text{ mg/kg}$  to about  $20 \text{ mg/kg}$ , in one or more dose administrations daily, for one or several days.

A therapeutically effective amount of an EC RTP/DEP-1 modulator of the present invention in the form of a polypeptide is typically an amount of  
10 polypeptide such that when administered in a physiologically tolerable composition is sufficient to achieve a plasma concentration of from about  $0.001 \text{ microgram } (\mu\text{g}) \text{ per milliliter } (\text{mL})$  to about  $10 \mu\text{g/mL}$ , preferably from about  $0.05 \mu\text{g/mL}$  to about  $1.0 \text{ ug/mL}$ . Based on a polypeptide having a mass of about  $15,000 \text{ grams per mole (i.e. } 15,000 \text{ Da)}$ , the preferred plasma concentration in  
15 molarity is from about  $0.0001 \text{ micro molar } (\mu\text{M})$  to about  $1 \text{ milli molar } (\text{mM})$ . Stated differently, the dosage per body weight can vary from about  $0.01 \text{ mg/kg}$  to about  $30 \text{ mg/kg}$ , and preferably from about  $0.05 \text{ mg/kg}$  to about  $20 \text{ mg/kg}$ , in one or more dose administrations daily, for one or several days.

The monoclonal antibodies or polypeptides of the invention can be  
20 administered parenterally by injection or by gradual infusion over time. Although the tissue to be treated can typically be accessed in the body by systemic administration and therefore most often treated by intravenous administration of therapeutic compositions, other tissues and delivery means are contemplated where there is a likelihood that the tissue targeted contains

the target molecule. Thus, monoclonal antibodies or polypeptides of the invention can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intra-cavity, transdermally, and can be delivered by peristaltic means.

5           The therapeutic compositions containing a monoclonal antibody or a polypeptide of the present invention are conventionally administered intravenously, as by injection of a unit dose, for example. The term "unit dose" when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for the subject,  
10       each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier or vehicle.

          The compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount. The quantity to  
15       be administered depends on the subject to be treated, capacity of the subject's system to utilize the active ingredient, and degree of therapeutic effect desired. Precise amounts of active ingredient required to be administered depend on the judgement of the practitioner and are peculiar to each individual. However, suitable dosage ranges for systemic application are disclosed herein and  
20       depend on the route of administration. Suitable regimes for administration are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous infusion sufficient to

maintain concentrations in the blood in the ranges specified for in vivo therapies are contemplated.

### C. Therapeutic Compositions

The present invention contemplates therapeutic compositions useful for practicing the therapeutic methods described herein. Therapeutic compositions of the present invention contain a physiologically tolerable carrier together with an ECRT/DEP-1 modulator as described herein, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the therapeutic ECRT/DEP-1 modulator composition is not immunogenic when administered to a mammal or human patient for therapeutic purposes.

As used herein, the terms "pharmaceutically acceptable", "physiologically tolerable" and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a mammal without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.

The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art and need not be limited based on formulation. Typically such compositions are prepared as injectables either as liquid solutions or suspensions; however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified.

The active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.

The therapeutic composition of the present invention can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

Physiologically tolerable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more

than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes.

Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions.

A therapeutic composition contains an angiogenesis-modulating amount of an EC RTP/DEP-1 modulator of the present invention, typically formulated to contain an amount of at least 0.1 weight percent of modulator per weight of total therapeutic composition. A weight percent is a ratio by weight of modulator to total composition. Thus, for example, 0.1 weight percent is 0.1 grams of inhibitor per 100 grams of total composition.

#### D. Modulators of EC RTP/DEP-1

EC RTP/DEP-1 modulators are used in the present methods for modulating EC RTP/DEP-1 activity in tissues, including modulating angiogenesis in tissues. Thus, as used herein, the terms "modulate", "modulating", and "modulator" are meant to be construed to encompass inhibiting, blocking, promoting, stimulating, agonising, antagonizing, or otherwise affecting EC RTP/DEP-1 activity in tissues.

Such modulators can take a variety of forms that include compounds which interact with the EC RTP/DEP-1 in a manner such that functional interactions with natural EC RTP/DEP-1 ligands are mimicked, stimulated and/or inhibited, such as, for example, dimerization of EC RTP/DEP-1. Exemplary modulators include analogs of an EC RTP/DEP-1 natural ligand



binding site on an EC RTP/DEP-1, mimetics of a natural ligand of an EC RTP/DEP-1 that mimic the structural region involved in an EC RTP/DEP-1-receptor ligand binding interactions, polypeptides having a sequence corresponding to the domain of a natural ligand of an EC RTP/DEP-1, and  
5 antibodies which immunoreact with either an EC RTP/DEP-1 or the natural ligand, all of which exhibit modulator activity as defined herein.

### 1. Polypeptides

In one embodiment, the invention contemplates EC RTP/DEP-1 modulators in the form of polypeptides. A polypeptide (peptide) EC RTP/DEP-1  
10 modulator interacts with the extracellular domain of EC RTP/DEP-1 and promotes dimerization of EC RTP/DEP-1. A preferred EC RTP/DEP-1 modulator peptide corresponds in sequence to the natural ligand and promotes or antagonizes dimerization of EC RTP/DEP-1 EC RTP/DEP-1.

In one embodiment, a polypeptide of the present invention comprises  
15 no more than about 100 amino acid residues, preferably no more than about 60 residues, more preferably no more than about 30 residues. Peptides can be linear or cyclic. Thus, it should be understood that a subject polypeptide need not be identical to the amino acid residue sequence of an EC RTP/DEP-1 natural ligand, so long as it includes required binding sequences and is able to  
20 function as an EC RTP/DEP-1 modulator in an assay such as is described herein.

A subject polypeptide includes any analog, fragment or chemical derivative of a polypeptide which is an EC RTP/DEP-1 modulator. Such a polypeptide can be subject to various changes, substitutions, insertions, and

deletions where such changes provide for certain advantages in its use. In this regard, an EC RTP/DEP-1 modulator polypeptide of the present invention corresponds to, rather than is identical to, the sequence of the natural ligand where one or more changes are made and it retains the ability to function as an EC RTP/DEP-1 modulator in one or more of the assays as defined herein. Thus, a polypeptide can be in any of a variety of forms of peptide derivatives, that include amides, conjugates with proteins, cyclized peptides, polymerized peptides, analogs, fragments, chemically modified peptides, and the like derivatives.

The term "analog" includes any polypeptide having an amino acid residue sequence substantially identical to a sequence of the natural ligand of the EC RTP/DEP-1 in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the EC RTP/DEP-1 modulator activity as described herein. Examples of conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another; the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine; the substitution of one basic residue such as lysine, arginine or histidine for another; or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another.

The phrase "conservative substitution" also includes the use of a chemically derivatized residue in place of a non-derivatized residue provided that such polypeptide displays the requisite inhibition activity.

"Chemical derivative" refers to a subject polypeptide having one or more residues chemically derivatized by reaction of a functional side group. Such derivatized molecules include for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups can be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups can be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine can be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids. For examples: 4-hydroxyproline can be substituted for proline; 5-hydroxylysine can be substituted for lysine; 3-methylhistidine can be substituted for histidine; homoserine can be substituted for serine; and ornithine can be substituted for lysine. Polypeptides of the present invention also include any polypeptide having one or more additions and/or deletions or residues relative to the sequence of a polypeptide whose sequence is shown herein, so long as the requisite activity is maintained. The term "fragment" refers to any subject polypeptide having an amino acid residue sequence shorter than that of a polypeptide disclosed herein.

When a polypeptide of the present invention has a sequence that is not identical to the sequence of an ECRT/DEP-1 natural ligand, it is typically because one or more conservative or non-conservative substitutions have been made, usually no more than about 30 number percent, and preferably no more

than 10 number percent of the amino acid residues are substituted. Additional residues can also be added at either terminus of a polypeptide for the purpose of providing a "linker" by which the polypeptides of the present invention can be conveniently affixed to a label or solid matrix, or carrier. Labels, solid  
5 matrices and carriers that can be used with the polypeptides of the present invention are described hereinbelow.

Amino acid residue linkers are usually at least one residue and can be 40 or more residues, more often 1 to 10 residues, but do not form EC RTP/DEP-1 ligand epitopes. Typical amino acid residues used for linking  
10 are tyrosine, cysteine, lysine, glutamic and aspartic acid, or the like. In addition, a subject polypeptide can differ, unless otherwise specified, from the natural sequence of an EC RTP/DEP-1 ligand by the sequence being modified by terminal-NH<sub>2</sub> acylation, e.g., acetylation, or thioglycolic acid amidation, by terminal-carboxylamidation, e.g., with ammonia, methylamine, and the like  
15 terminal modifications. Terminal modifications are useful, as is well known, to reduce susceptibility by proteinase digestion, and therefore serve to prolong half life of the polypeptides in solutions, particularly biological fluids where proteases can be present. In this regard, polypeptide cyclization is also a useful terminal modification, and is particularly preferred also because of the  
20 stable structures formed by cyclization and in view of the biological activities observed for such cyclic peptides as described herein.

Any peptide of the present invention can be used in the form of a pharmaceutically acceptable salt. Suitable acids which are capable of the peptides with the peptides of the present invention include inorganic acids such

as trifluoroacetic acid (TFA), hydrochloric acid (HCl), hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, 5 naphthalene sulfonic acid, sulfanilic acid or the like. HCl and TFA salts are particularly preferred.

Suitable bases capable of forming salts with the peptides of the present invention include inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like; and organic bases such as mono- 10 di- and tri-alkyl and aryl amines (e.g. triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like), and optionally substituted ethanolamines (e.g. ethanolamine, diethanolamine and the like).

A peptide of the present invention, also referred to herein as a subject polypeptide, can be synthesized by any of the techniques that are known to 15 those skilled in the polypeptide art, including recombinant DNA techniques. Synthetic chemistry techniques, such as a solid-phase Merrifield-type synthesis, are preferred for reasons of purity, antigenic specificity, freedom from undesired side products, ease of production and the like. An excellent summary of the many techniques available can be found in Steward et al., 20 "Solid Phase Peptide Synthesis", W. H. Freeman Co., San Francisco, 1969; Bodanszky, et al., "Peptide Synthesis", John Wiley & Sons, Second Edition, 1976; J. Meienhofer, "Hormonal Proteins and Peptides", Vol. 2, p. 46, Academic Press (New York), 1983; Merrifield, *Adv Enzymol*, 32:221-96, 1969; Fields et al., *Int. J. Peptide Protein Res.*, 35:161-214, 1990; and U.S. Pat. No.

4,244,946 for solid phase peptide synthesis, and Schroder et al., "The Peptides", Vol. 1, Academic Press (New York), 1965 for classical solution synthesis, each of which is incorporated herein by reference. Appropriate protective groups usable in such synthesis are described in the above texts and  
5 in J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, New York, 1973, which is incorporated herein by reference.

In general, the solid-phase synthesis methods contemplated comprise the sequential addition of one or more amino acid residues or suitably protected amino acid residues to a growing peptide chain. Normally, either the  
10 amino or carboxyl group of the first amino acid residue is protected by a suitable, selectively removable protecting group. a different, selectively removable protecting group is utilized for amino acids containing a reactive side group such as lysine.

Using a solid phase synthesis as exemplary, the protected or derivatized  
15 amino acid is attached to an inert solid support through its unprotected carboxyl or amino group. The protecting group of the amino or carboxyl group is then selectively removed and the next amino acid in the sequence having the complimentary (amino or carboxyl) group suitably protected is admixed and reacted under conditions suitable for forming the amide linkage with the residue  
20 already attached to the solid support. The protecting group of the amino or carboxyl group is then removed from this newly added amino acid residue, and the next amino acid (suitably protected) is then added, and so forth. After all the desired amino acids have been linked in the proper sequence, any

remaining terminal and side group protecting groups (and solid support) are removed sequentially or concurrently, to afford the final linear polypeptide.

The resultant linear polypeptides prepared for example as described above can be reacted to form their corresponding cyclic peptides. An exemplary method for cyclizing peptides is described by Zimmer et al., *Peptides* 1992, pp. 393-394, ESCOM Science Publishers, B. V., 1993. Typically, tertbutoxycarbonyl protected peptide methyl ester is dissolved in methanol and sodium hydroxide solution are added and the admixture is reacted at 20°C to hydrolytically remove the methyl ester protecting group.

After evaporating the solvent, the tertbutoxycarbonyl protected peptide is extracted with ethyl acetate from acidified aqueous solvent. The tertbutoxycarbonyl protecting group is then removed under mildly acidic conditions in dioxane cosolvent. The unprotected linear peptide with free amino and carboxy termini so obtained is converted to its corresponding cyclic peptide by reacting a dilute solution of the linear peptide, in a mixture of dichloromethane and dimethylformamide, with dicyclohexylcarbodiimide in the presence of 1-hydroxybenzotriazole and N-methylmorpholine. The resultant cyclic peptide is then purified by chromatography.

## 2. Antibodies

The present invention describes, in one embodiment, EC RTP/DEP-1 modulators in the form of antibodies, including monoclonal antibodies, which immunoreact with an EC RTP/DEP-1 and bind the EC RTP/DEP-1 to modulate receptor activity as described herein. The invention also describes cell lines

which produce the antibodies, methods for producing the cell lines, and methods for producing the antibodies, including monoclonal antibodies.

An antibody of the present invention can comprise an antibody molecule that 1) immunoreact with isolated EC RTP/DEP-1, and 2) bind to the EC RTP/DEP-1 to modulate its biological function. Preferably, an antibody of the present invention preferentially binds the EC RTP/DEP-1 ectodomain, which comprises amino acids 1-351 of EC RTP/DEP-1. More preferably, an antibody of the present invention preferentially binds an eight amino acid epitope having the sequence n-QSRDTEVL-c, or an eight amino acid epitope having an analog sequence of the sequence n-QSRDTEVL-c, the term "analog" as defined herein, of the EC RTP/DEP-1 ectodomain.

Preferred monoclonal antibodies which preferentially bind to EC RTP/DEP-1 include a monoclonal antibody having the immunoreaction characteristics of Mab EC RTPAb-1, having molecular weight of about 150 KDa respectively and which binds to the ectodomain of the EC RTP/DEP-1, as is described herein below. Mab EC RTPAb-1 is preferably secreted by hybridoma cell line ATCC HB12570. The hybridoma cell line ATCC HB12570 was deposited pursuant to Budapest Treaty requirements with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Virginia, 20110-2209, U.S.A., on September 18, 1998.

The term "antibody or antibody molecule" in the various grammatical forms is used herein as a collective noun that refers to a population of immunoglobulin molecules and/or immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antibody combining



site or paratope. An "antibody combining site" is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen.

Exemplary antibodies for use in the present invention are intact  
5 immunoglobulin molecules, substantially intact immunoglobulin molecules, single chain immunoglobulins or antibodies, those portions of an immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab', F(ab')<sub>2</sub> and F(v), and also referred to as antibody fragments.

10 Indeed, as described in the Examples set forth below, an Fab fragment, that is, a monovalent fragment, of the Mab ECRTAb-1 releases density arrest. Thus, it is contemplated to be within the scope of the present invention that such a monovalent modulator is used to promote angiogenesis, or to promote endothelial cell migration and proliferation, or to release inhibitory influences  
15 on endothelial cells to serve as an adjunctive to other angiogenic stimuli. Thus, the terms "modulate", "modulating", and "modulator" are meant to be construed to encompass such promotion.

The phrase "monoclonal antibody" in its various grammatical forms refers to a population of antibody molecules that contain only one species of  
20 antibody combining site capable of immunoreacting with a particular epitope. A monoclonal antibody thus typically displays a single binding affinity for any epitope with which it immunoreacts. A monoclonal antibody can therefore contain an antibody molecule having a plurality of antibody combining sites,

each immunospecific for a different epitope, e.g., a bispecific monoclonal antibody.

A monoclonal antibody is typically composed of antibodies produced by clones of a single cell called a hybridoma that secretes (produces) only one kind of antibody molecule. The hybridoma cell is formed by fusing an antibody-producing cell and a myeloma or other self-perpetuating cell line. The preparation of such antibodies was first described by Kohler and Milstein, *Nature* 256:495-497 (1975), which description is incorporated by reference. Additional methods are described by Zola, *Monoclonal Antibodies: a Manual of Techniques*, CRC Press, Inc. (1987). The hybridoma supernates so prepared can be screened for the presence of antibody molecules that immunoreact with an ECRT/DEP-1 and for inhibition of an ECRT/DEP-1 to activate its biological function.

Briefly, to form the hybridoma from which the monoclonal antibody composition is produced, a myeloma or other self-perpetuating cell line is fused with lymphocytes obtained from the spleen of a mammal hyperimmunized with a source of an ECRT/DEP-1, as described by Cheresch et al., *J. Biol Chem*, 262:17703-17711 (1987).

It is preferred that the myeloma cell line used to prepare a hybridoma be from the same species as the lymphocytes. Typically, a mouse of the strain 129 GIX+ is the preferred mammal. Suitable mouse myelomas for use in the present invention include the hypoxanthine-aminopterin-thymidine-sensitive (HAT) cell lines P3X63-Ag8.653, and Sp2/O-Ag14 that are available from the

ATCC, Manassas, Virginia, under the designations CRL 1580 and CRL 1581, respectively.

Splenocytes are typically fused with myeloma cells using polyethylene glycol (PEG) 1500. Fused hybrids are selected by their sensitivity to HAT.

- 5 Hybridomas producing a monoclonal antibody of the present invention are identified using the enzyme linked immunosorbent assay (ELISA) described in the Examples.

- A monoclonal antibody of the present invention can also be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium  
10 containing a hybridoma that secretes antibody molecules of the appropriate specificity. The culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium. The antibody-containing medium is then collected. The antibody molecules can then be further isolated by well known techniques. Media useful for the  
15 preparation of these compositions are both well known in the art and commercially available and include synthetic culture media, inbred mice and the like. An exemplary synthetic medium is Dulbecco's minimal essential medium (DMEM - Dulbecco et al., *Virology* 8:396 (1959)) supplemented with 4.5 gm/1 glucose, 20 mM glutamine, and 20% fetal calf serum. An exemplary  
20 inbred mouse strain is the Balb/C.

Other methods of producing a monoclonal antibody, a hybridoma cell, or a hybridoma cell culture are also well known. See, for example, the method of isolating monoclonal antibodies from an immunological repertoire as

described by Sastry, et al., *Proc Natl Acad Sci USA* 86:5728-5732 (1989); and Huse et al., *Science* 246:1275-1281 (1989).

Also contemplated by the present invention is the hybridoma cell, and cultures containing a hybridoma cell that produce a monoclonal antibody of the present invention. Particularly preferred is the hybridoma cell line that secretes monoclonal antibody Mab ECRTAb-1 as described in the Examples presented below and as designated ATCC HB12570. Mab ECRTAb-1 was prepared as described in the Examples. The invention thus contemplates, in one embodiment, a monoclonal antibody that has the immunoreaction characteristics of Mab ECRTAb-1.

It is also possible to determine, without undue experimentation, if a monoclonal antibody has the same (i.e., equivalent) specificity (immunoreaction characteristics) as a monoclonal antibody of the present invention by ascertaining whether the former prevents the latter from binding to a preselected target molecule. If the monoclonal antibody being tested competes with the monoclonal antibody of the invention, as shown by a decrease in binding by the monoclonal antibody of the invention in standard competition assays for binding to the target molecule when present in the solid phase, then it is likely that the two monoclonal antibodies bind to the same, or a closely related, epitope. A preferred target molecule comprises a polypeptide fragment of the ECRT/DEP-1 ectodomain includes an eight amino acid epitope having the sequence n-QSRDTEVL-c, or an eight amino acid epitope having an analog sequence of the sequence n-QSRDTEVL-c, the term "analog" as defined herein.

Still another way to determine whether a monoclonal antibody has the specificity of a monoclonal antibody of the invention is to pre-incubate the monoclonal antibody of the invention with the target molecule with which it is normally reactive, and then add the monoclonal antibody being tested to determine if the monoclonal antibody being tested is inhibited in its ability to bind the target molecule. If the monoclonal antibody being tested is inhibited then, in all likelihood, it has the same, or functionally equivalent, epitopic specificity as the monoclonal antibody of the invention. A preferred target molecule comprises a polypeptide fragment of the ECRT/DEP-1 ectodomain includes an eight amino acid epitope having the sequence n-QSRDTEVL-c, or an eight amino acid epitope having an analog sequence of the sequence n-QSRDTEVL-c, the term "analog" as defined herein.

An additional way to determine whether a monoclonal antibody has the specificity of a monoclonal antibody of the invention is to determine the amino acid residue sequence of the CDR regions of the antibodies in question. Antibody molecules having identical, or functionally equivalent, amino acid residue sequences in their CDR regions have the same binding specificity. Methods for sequencing polypeptides are well known in the art.

The immunospecificity of an antibody, its target molecule binding capacity, and the attendant affinity the antibody exhibits for the epitope, are defined by the epitope with which the antibody immunoreacts. The epitope specificity is defined at least in part by the amino acid residue sequence of the variable region of the heavy chain of the immunoglobulin that comprises the antibody, and in part by the light chain variable region amino acid residue

sequence. Use of the terms "having the binding specificity of" or "having the binding preference of" indicates that equivalent monoclonal antibodies exhibit the same or similar immunoreaction (binding) characteristics and compete for binding to a preselected target molecule. Preferably, an antibody of the

5 present invention preferentially binds an eight amino acid epitope having the sequence n-QSRDTEVL-c, or an eight amino acid epitope having an analog sequence of the sequence n-QSRDTEVL-c, the term "analog" as defined herein, of the ECRT/DEP-1 ectodomain.

Humanized monoclonal antibodies offer particular advantages over

10 murine monoclonal antibodies, particularly insofar as they can be used therapeutically in humans. Specifically, human antibodies are not cleared from the circulation as rapidly as "foreign" antigens, and do not activate the immune system in the same manner as foreign antigens and foreign antibodies. Methods of preparing "humanized" antibodies are generally well known in the

15 art, and can readily be applied to the antibodies of the present invention. Thus, the invention contemplates, in one embodiment, a monoclonal antibody of the present invention that is humanized by grafting to introduce components of the human immune system without substantially interfering with the ability of the antibody to bind antigen. Humanized antibodies can also be produced using

20 animals engineering to produce humanized antibodies, such as those available from Medarex of Annandale, New Jersey (mice) and Abgenix, Inc., of Fremont, California (mice).

The use of a molecular cloning approach to generate antibodies, particularly monoclonal antibodies, and more particularly single chain

monoclonal antibodies, is also contemplated. The production of single chain antibodies has been described in the art, see e.g., U.S. Patent No. 5,260,203, the contents of which are herein incorporated by reference. For this, combinatorial immunoglobulin phagemid or phage-displayed libraries are prepared from RNA isolated from the spleen of the immunized animal, and phagemids expressing appropriate antibodies are selected by panning on endothelial tissue. This approach can also be used to prepared humanized antibodies. The advantages of this approach over conventional hybridoma techniques are that approximately  $10^4$  times as many antibodies can be produced and screened in a single round, and that new specificities are generated by H and L chain combination in a single chain, which further increases the chance of finding appropriate antibodies. Thus, an antibody of the present invention, or a "derivative" of an antibody of the present invention pertains to a single polypeptide chain binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the light and heavy chain aggregate variable region of an antibody described herein, such as EC RTP/DEP-1. Preferably, an antibody of the present invention preferentially binds an eight amino acid epitope having the sequence n-QSRDTEVL-c, or an eight amino acid epitope having an analog sequence of the sequence n-QSRDTEVL-c, the term "analog" as defined herein, of the EC RTP/DEP-1 ectodomain.

"Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. In a two-chain Fv species, this region consists of a dimer of one heavy- and one light-chain variable domain in tight,

non-covalent association. In a single-chain Fv species (scFv), one heavy- and one light-chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a "dimeric" structure analogous to that in a two-chain Fv species. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site. For a review of scFv see Pluckthun, in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

Using a phage-displayed approach for the production of antibodies, scFv antibody clones that bind to the EC RTP/DEP-1 ectodomain have been identified. This was accomplished by competing off those phage displayed antibodies using EC RTPAb-1 disclosed herein. Fv regions are sequenced and bivalent functional reagents are designed and tested in a screening assay of the present invention disclosed herein below. Thus, a preferred source for an antibody, or derivative or fragment thereof, is a recombinant phage-displayed antibody library. The recombinant phage can comprise antibody encoding nucleic acids isolated from any suitable vertebrate species, including mammalian species such as mouse and rat; but preferably comprises antibody encoding nucleic acids isolated from human. Such antibodies are thus already "humanized".



### 3. Other Modulators

It is also envisioned that previously described and newly discovered angiogenesis inhibiting or endothelial cell growth suppressing chemical compounds are modulators of EC RTP/DEP-1 activity in tissues. Examples of such compounds include, but are not limited to, angiostatin, endostatin and thrombospondin. Accordingly, such compounds can be used in the modulation of EC RTP/DEP-1 activity in tissues, according to the methods of the present invention.

Given the disclosure of the EC RTP/DEP-1 activity in tissues herein, it is also contemplated that as yet undefined chemical compounds can be used to modulate EC RTP/DEP-1 activity in tissues in accordance with the methods of the present invention. In one embodiment, a modulator of the present invention interacts with an eight amino acid epitope having the sequence n-QSRDTEVL-c of the EC RTP/DEP-1 ectodomain. In another embodiment, a modulator of the present invention interacts with an intracellular catalytic domain of EC RTP/DEP-1. The identification of such modulators is provided through the description of screening assays directed to EC RTP/DEP-1 activity in tissues presented herein.

### D. Screening Assay

Skilled artisans will understand that the disclosure herein of the localization and function of the EC RTP/DEP-1, and in vitro assays relating to such localization and function, provides opportunities to screen for compounds that modulate, whether partially or completely, the functional activity of the

ECRTP/DEP-1. In this context, "modulate" is intended to mean that the subject compound increases or decreases one or more functional activities of the ECRTP/DEP-1, such as but not limited to ECRTP/DEP-1 activity in cell growth, cell survival and angiogenesis.

5           Further, the screening assays illustrated in the Examples below include biochemical assays (e.g., measuring effects of anti-ECRTP/DEP-1 monoclonal antibodies on ECRTP/DEP-1 activity), and cellular in vitro assays (e.g., measuring the effects of ECRTP/DEP-1 over-expression on endothelial cell proliferation and migration and/or evaluating ECRTP/DEP-1 phosphorylation).  
10       The illustrative biochemical assays can be particularly useful in screening for compounds modulating an ECRTP/DEP-1 activity, while the cellular assays can be particularly useful in screening for compounds completely altering an ECRTP/DEP-1 activity. Thus, until the disclosure herein of the role of the ECRTP/DEP-1 in regulating cell growth, cell survival, endothelial cell  
15       proliferation and migration and in regulating angiogenesis, a motivation to screen for compounds that modulate ECRTP/DEP-1 activity was lacking in the prior art.

          Those skilled in the art will understand that binding of a ligand at a molecular binding site can be modulated in a direct matter (e.g., by blocking the  
20       site), as well as modulated in an indirect manner (e.g., by conformational changes induced following binding of a second, i.e., different, ligand at a distant site). In this regard, it is likely that the binding site specificity of an ECRTP/DEP-1 for its endogenous ligand can be completely modulated or altered (i.e., to bind a different ligand) by agents that bind at distant sites in the

ECRTP/DEP-1. Examples of compounds that can be screened in the latter several assays include at least nucleic acids (e.g., DNA oligonucleotide aptamers that bind proteins and alter their functions), proteins, antibodies and antibody fragments, carbohydrates, lectins, organic chemicals, and the like.

- 5 Such screening assays can be useful for identifying candidate therapeutic agents that can provide drugs useful in animals and humans.

It is still further understood that due to the significance of the ECRTP/DEP-1 in cell growth, cell survival, endothelial cell migration and proliferation, in density induced growth arrest, and in modulation of  
10 angiogenesis, innate regulatory mechanisms exist in cells for regulating their activity by binding to an ECRTP/DEP-1, or to complexes containing an ECRTP/DEP-1. Such regulatory factors can include, at least: (a) cofactors that bind to the complex and exert regulatory action by destabilizing or stabilizing the complex; (b) agents that modulate or alter the activity of the complex by  
15 inducing conformational changes in the ECRTP/DEP-1 as they are bound in a complex; (c) enzymes that inactivate one or both members of a complex; and (d) cellular control factors (e.g., signal transduction second messengers, transcription regulating factors, DNA replication factors and the like) that bind an ECRTP/DEP-1 or ECRTP/DEP-1 complexes and modulate or alter  
20 functional activity. Those skilled in the art will recognize that the functional regions of an ECRTP/DEP-1 represent particularly attractive targets for three-dimensional molecular modeling and for construction of mimetic compounds, e.g., organic chemicals constructed to mimic the three-dimensional interactions

between the EC RTP/DEP-1 and its endogenous binding partner, or other binding partner.

Utilizing the methods and compositions of the present invention, screening assays for the testing of candidate substances can be derived. A candidate substance is a substance which potentially can modulate endothelial cell growth, cell survival, cell migration and proliferation, density induced growth arrest and/or angiogenesis, and/or EC RTP/DEP-1 phosphorylation, by binding or other intramolecular interaction, with an EC RTP/DEP-1 that modulates endothelial cell growth, cell survival, cell migration and proliferation, density induced growth arrest and angiogenesis.

Thus, a method of screening candidate substances for an ability to modulate EC RTP/DEP-1 biological activity is also disclosed. The method comprises establishing a test sample comprising an EC RTP/DEP-1 polypeptide or fragment thereof; administering a candidate substance to the test sample; and measuring the interaction, effect, or combination thereof, of the candidate substance on the test sample to thereby determine the ability of the candidate substance to modulate EC RTP/DEP-1 biological activity.

The present invention also provides a process of screening substances for their ability to modulate or alter cell growth, cell survival, endothelial cell migration and proliferation, density induced growth arrest and/or angiogenesis and/or EC RTP/DEP-1 phosphorylation comprising the steps of providing a cell that contains a functional EC RTP/DEP-1 and testing the ability of selected substances to modulate or alter cell growth, cell survival, migration or proliferation of that cell, density induced growth arrest of the cell, or initiation

of angiogenesis in the cell and/or evaluating EC RTP/DEP-1 phosphorylation in the cell.

A screening assay of the present invention generally involves determining the ability of a candidate substance to affect cell growth, cell survival, endothelial cell migration and proliferation, density induced growth arrest and/or angiogenesis, and/or EC RTP/DEP-1 phosphorylation in a target cell, such as the screening of candidate substances to identify those that modulate or alter cell growth, cell survival, endothelial cell migration and proliferation, density induced growth arrest and/or angiogenesis, and/or EC RTP/DEP-1 phosphorylation. Target cells can be either naturally occurring cells known to contain an EC RTP/DEP-1 or transfected cell produced in accordance with a process of transfection set forth herein and as are known in the art.

Thus, in one embodiment a method of screening a candidate substance for an ability to modulate a receptor tyrosine phosphatase in accordance with the present invention comprises establishing test samples comprising a receptor tyrosine phosphatase polypeptide; and administering a candidate substance to the test samples; measuring the interaction, effect, or combination thereof, of the candidate substance on the test sample to thereby determine the ability of the candidate substance to modulate receptor tyrosine phosphatase biological activity. A preferred receptor tyrosine phosphatase comprises EC RTP/DEP-1.

In another embodiment, a method of screening a candidate substance for an ability to modulate a receptor tyrosine phosphatase in accordance with

the present invention comprises establishing a test sample comprising a receptor tyrosine phosphatase; administering a candidate substance to the test sample; and measuring a receptor tyrosine phosphatase biological activity in the test sample; detecting phosphotyrosine residues on the receptor tyrosine phosphatase; and determining that the candidate substance modulates the receptor tyrosine phosphatase if the receptor tyrosine phosphatase biological activity measured for the test sample is greater or less than the receptor tyrosine phosphatase biological activity measured for a control sample and if the amount of phosphotyrosine residues on the receptor tyrosine phosphatase is greater or less than an amount of phosphotyrosine residues on a receptor tyrosine phosphate derived from a control sample. A preferred receptor tyrosine phosphatase comprises ECRT/DEP-1.

In yet another embodiment, a method of screening a candidate substance for an ability to modulate a receptor tyrosine phosphatase in accordance with the present invention comprises establishing replicate test and control cultures of cells that express the ECRT/DEP-1; administering a candidate compound to the cells in the test culture but not the control culture; measuring ECRT/DEP-1 activity in cells in the test and the control cultures; and determining that the candidate compound modulates the ECRT/DEP-1 activity in a cell if the ECRT/DEP-1 activity measured for the test culture is greater or less than the ECRT/DEP-1 activity measured for the control culture.

The screening assay methods of the present invention also pertain to comparing the effect of a candidate compound to inhibit growth of cells expressing exogenous ECRT/DEP-1 compared with those not expressing

ECRTP/DEP-1 and determining that the effect of altering ECRTP/DEP-1 activity is responsible by demonstrating the lack of activity of the candidate compound on cells not expressing ECRTP/DEP-1. The screening assays of the present invention show changes in growth that are responsive to changes in ECRTP/DEP-1 activity. For example, the screening methods of the present invention are used to screen for biologically active counter-receptors (ligands) by screening for growth inhibitory activity in biological fractions (plasma, cell lysates, cell membrane extracted proteins) by comparing growth inhibition on CHO/ECRTP/DEP-1 to CHO parent cell lines.

10 In a cell-free system, a method of screening a candidate substance for an ability to modulate a receptor tyrosine phosphatase in accordance with the present invention comprises establishing a control system comprising an ECRTP/DEP-1, or fragment thereof and a ligand wherein the ECRTP/DEP-1 is capable of binding to the ligand; establishing a test system comprising the ECRTP/DEP-1, the ligand, and a candidate compound; measuring the binding affinity of the ECRTP/DEP-1 and the ligand in the control and the test systems; and determining that the candidate compound modulates ECRTP/DEP-1 activity in a cell-free system if the binding affinity measured for the test system is less than or greater than the binding affinity measured for the control system.

15

20 Optionally, the ligand comprises an antibody which preferentially binds the ECRTP/DEP-1. In this case, it is preferred that the ligand comprise a monoclonal antibody.

In accordance with the present invention, a method of affinity screening of candidate modulator substances, including but not limited to antibodies, is

provided. The method comprises: (a) contacting a candidate modulator substance with an EC RTP/DEP-1 polypeptide or fragment thereof under conditions favorable to binding the candidate modulator substance with an EC RTP/DEP-1 polypeptide or fragment thereof to form a complex  
5 therebetween; and (b) detecting the complex.

The complex can be detected in any suitable manner. For example, the complex can be detected via a label conjugated to the EC RTP/DEP-1 polypeptide or fragment thereof; via a labeled reagent that specifically binds to the complex subsequent to its formation; or via a competition assay with a  
10 substance. The EC RTP/DEP-1 polypeptide fragment can be a EC RTP/DEP-1 ectodomain fragment. Preferably, the EC RTP/DEP-1 ectodomain fragment comprises an eight amino acid epitope having the sequence n-QSRDTEVL-c, or an eight amino acid epitope having an analog sequence of the sequence n-QSRDTEVL-c, the term "analog" as defined herein. Optionally, the  
15 EC RTP/DEP-1 polypeptide or fragment thereof is conjugated with a detectable label. In this case, the detecting step comprises: (i) separating the complex from unbound labeled binding substance; and (ii) detecting the detectable label which is present in the complex or which is unbound.

An antibody, or derivative or fragment thereof, can be screened as a  
20 candidate modulator substance. As noted above, a preferred source for an antibody, or derivative or fragment thereof, is a recombinant phage-displayed antibody library. The recombinant phage can comprise antibody encoding nucleic acids isolated from any suitable vertebrate species, including mammalian species such as mouse and rat; but preferably comprises antibody



encoding nucleic acids isolated from human. Such antibodies are thus already "humanized".

In another aspect, the present invention pertains to a kit for use in the aforementioned affinity screening method. The kit comprises a binding agent  
5 comprising a polypeptide fragment of the EC RTP/DEP-1 ectodomain that comprises an eight amino acid epitope having the sequence n-QSRDTEVL-c, or an eight amino acid epitope having an analog sequence of the sequence n-QSRDTEVL-c, the term "analog" as defined herein, contained in a first container. Optionally, the binding agent can be immobilized to a solid phase  
10 support, or the kit can also comprise a solid phase support contained in a second container.

The kit can further comprise a reagent or indicator that comprises a detectable label, the indicator containing in another container. Alternatively, the binding agent can comprise a detectable label or indicator. Preferably, the  
15 indicator is a radioactive label or an enzyme, or other suitable indicator.

Another technique for drug screening which can be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO 84/03564, herein incorporated by reference. In this method, as applied to the  
20 EC RTP/DEP-1 polypeptide, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with the EC RTP/DEP-1 polypeptide, or fragments thereof, and washed. Bound EC RTP/DEP-1 polypeptide is then detected by methods well known in the art. Purified EC RTP/DEP-1 polypeptide

can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

A screening assay of the present invention can also involve determining  
5 the ability of a candidate substance to modulate, *i.e.* inhibit or promote  
ECRTP/DEP-1 biological activity and preferably, to thereby modulate the  
ECRTP/DEP-1 biological activity in target cells. Target cells can be either  
naturally occurring cells known to contain a polypeptide of the present invention  
or transfected cells produced in accordance with a process of transfection set  
10 forth herein above. The test samples can further comprise a cell or cell line  
that expresses the ECRTP/DEP-1; the present invention also contemplates a  
recombinant cell line suitable for use in the exemplary method. Such cell lines  
can be mammalian, or human, or they can from another organism, including  
but not limited to yeast. Exemplary assays including genetic screening assays  
15 and molecular biology screens such as a yeast two-hybrid screen that will  
effectively identify ECRTP/DEP-1 -interacting genes important for endothelial  
cell migration and proliferation, density induced growth arrest, angiogenesis or  
other ECRTP/DEP-1-mediated cellular process. One version of the yeast two-  
hybrid system has been described (Chien *et al.*, 1991, *Proc. Natl. Acad. Sci.*  
20 *USA*, 88:9578-9582) and is commercially available from Clontech (Palo Alto,  
California).

A method of identifying modulators of the ECRTP/DEP-1 by rational  
drug design is also provided in accordance with the present invention. The  
method comprises the steps of designing a potential modulator for the

ECRTP/DEP-1 that will form non-covalent bonds with amino acids in the substrate binding site in the catalytic domain (an intracellular site) or with the ECRTP/DEP-1 ectodomain based upon the structure of the ECRTP/DEP-1; synthesizing the modulator; and determining whether the potential modulator modulates the activity of the ECRTP/DEP-1.

Thus, the present invention pertains to screening and rational drug design methods for both ectodomain interactions, as well as catalytic modulators. For example, catalytic antagonists that release cells from growth arrest through modulation of the catalytic function independent of the ectodomain can be screened and designed. Additionally, a modulator of the present invention can be screened for interaction with an eight amino acid epitope having the sequence n-QSRDTEVL-c, or an eight amino acid epitope having an analog sequence of the sequence n-QSRDTEVL-c, the term "analog" as defined herein, of the ECRTP/DEP-1 ectodomain.

Modulators can be synthesized using techniques disclosed herein and as are known in the art. The determination of whether the modulator modulates the biological activity of the ECRTP/DEP-1 is made in accordance with the screening methods disclosed herein, or by other screening methods known in the art.

As is well known in the art, a screening assay provides a cell under conditions suitable for testing modulation or alteration of cell growth, cellendothelial cell migration and proliferation, density induced growth arrest, angiogenesis, and/or ECRTP/DEP-1 phosphorylation. These conditions include but are not limited to pH, temperature, tonicity, the presence of relevant

factors involved in the cell cycle (e.g., growth factors), and relevant modifications to the polypeptide such as glycosylation or prenylation. It is contemplated that an EC RTP/DEP-1 can be expressed and utilized in a prokaryotic or eukaryotic cell. The host cell can also be fractionated into sub-cellular fractions where the receptor can be found. For example, cells expressing the polypeptide can be fractionated into the nuclei, the endoplasmic reticulum, vesicles, or the membrane surfaces of the cell.

pH is preferably from about a value of 6.0 to a value of about 8.0, more preferably from about a value of about 6.8 to a value of about 7.8 and, most preferably about 7.4. In a preferred embodiment, temperature is from about 20°C to about 50°C, more preferably from about 30°C to about 40°C and, even more preferably about 37°C. Osmolality is preferably from about 5 milliosmols per liter (mosm/L) to about 400 mosm/l and, more preferably from about 200 milliosmols per liter to about 400 mosm/l and, even more preferably from about 290 mosm/L to about 310 mosm/L. The presence of factors can be required for the proper testing of endothelial cell migration and proliferation, density induced growth arrest and/or angiogenesis in specific cells. Such factors include, for example, the presence and absence (withdrawal) of growth factor, interleukins, or colony stimulating factors.

## 20 E. Methods For Identifying Modulators of an EC RTP/DEP-1

The invention thus also pertains to assay methods for identifying candidate EC RTP/DEP-1 modulators. In these assay methods candidate molecules are evaluated for their potency in agonising an EC RTP/DEP-1

binding to natural ligands, and furthermore are evaluated for their potency in modulating angiogenesis in a tissue.

5 An exemplary assay measures angiogenesis in the chick chorioallantoic membrane (CAM) and is referred to as the CAM assay. The CAM assay has be described in detail by others, and further has been used to measure both angiogenesis and neovascularization of tumor tissues. See Ausprunk et al., *Am J Pathol* 79:597–618 (1975) and Ossonski et al., *Cancer Res* 40:2300–2309 (1980).

10 The CAM assay is a well recognized assay model for in vivo angiogenesis because neovascularization of whole tissue is occurring, and actual chick embryo blood vessels are growing into the CAM or into the tissue grown on the CAM. The CAM assay illustrates inhibition of neovascularization based on both the amount and extent of new vessel growth. Furthermore, it is easy to monitor the growth of any tissue transplanted upon the CAM, such  
15 as a tumor tissue. Finally, the assay is particularly useful because there is an internal control for toxicity in the assay system. The chick embryo is exposed to any test reagent, and therefore the health of the embryo is an indication of toxicity.

20 F. Preparation of Targeting Agent/toxin Compounds, Including Immunotoxins

Methods for the production of the target agent/toxin agent compounds of the invention are described herein. The targeting agents, such as antibodies, of the invention can be linked, or operatively attached, to the toxins of the

invention by either crosslinking or via recombinant DNA techniques, to produce, for example, targeted immunotoxins.

While the preparation of immunotoxins is, in general, well known in the art (see e.g., U.S. Pat. Nos. 4,340,535 and 5,776,427, and EP 44167, each of which incorporated herein by reference), certain advantages can be achieved through the application of certain preferred technology, both in the preparation of the immunotoxins and in their purification for subsequent clinical administration. For example, while numerous types of disulfide-bond containing linkers are known which can successfully be employed to conjugate the toxin moiety with the targeting agent, certain linkers will generally be preferred over other linkers, based on differing pharmacologic characteristics and capabilities. For example, linkers that contain a disulfide bond that is sterically "hindered" are to be preferred, due to their greater stability *in vivo*, thus preventing release of the toxin moiety prior to binding at the site of action.

A wide variety of cytotoxic agents are known that can be conjugated to anti-endothelial cell antibodies. Examples include numerous useful plant-, fungus- or even bacteria-derived toxins, which, by way of example, include various A chain toxins, particularly ricin A chain, ribosome inactivating proteins such as saporin or gelonin, a -sarcin, aspergillin, restrictocin, ribonucleases such as placental ribonuclease, angiogenic, diphtheria toxin, and pseudomonas exotoxin, to name just a few.

However, it can be desirable from a pharmacologic standpoint to employ the smallest molecule possible that nevertheless provides an appropriate

biological response. One can thus desire to employ smaller-chain peptides which will provide an adequate anti-cellular response.

Alternatively, one can find that the application of recombinant DNA technology to the toxin moiety will provide additional significant benefits in accordance the invention. For example, the cloning and expression of biologically active toxin candidates has now been described through the publications of others (O'Hare et al., *FEBS Lett* 210:731 (1987); Lamb et al., *Eur Jmol Biochem* 148:265-270 (1985); Hailing et al., *Nucl Acids Res* 13:8019-8033 (1985)), it is now possible to identify and prepare smaller or otherwise variant peptides which nevertheless exhibit an appropriate toxin activity. Moreover, the use of cloned toxin candidates allows the application of site-directed mutagenesis, through which one can readily prepare and screen for mutated peptides and obtain additional useful moieties for use in connection with the present invention.

In cases where a releasable toxin is contemplated, one desires to have a conjugate that will remain intact under conditions found everywhere in the body except the intended site of action, at which point it is desirable that the conjugate have good "release" characteristics. Therefore, the particular cross-linking scheme, including the particular cross-linking reagent used and the structures that are cross-linked, will be of some significance.

Cross-linking reagents are used to form molecular bridges that tie together functional groups of two different proteins (e.g., a toxin and a binding agent). To link two different proteins in a step-wise manner, heterobifunctional cross-linkers can be used which eliminate the unwanted homopolymer

formation. An exemplary heterobifunctional cross-linker contains two reactive groups: one reacting with primary amine group (e.g., N-hydroxy succinimide) and the other reacting with a thiol group (e.g., pyridyl disulfide, maleimides, halogens, etc.). Through the primary amine reactive group, the cross-linker  
5 can react with the lysine residue(s) of one protein (e.g., the selected antibody or fragment) and through the thiol reactive group, the cross-linker, already tied up to the first protein, reacts with the cysteine residue (free sulfhydryl group) of the other protein.

The spacer arm between these two reactive groups of any cross-linkers  
10 can have various length and chemical composition. A longer spacer arm allows a better flexibility of the conjugate components while some particular components in the bridge (e.g., benzene group) can lend extra stability to the reactive group or an increased resistance of the chemical link to the action of various aspects (e.g., disulfide bond resistant to reducing agents).

15 An exemplary cross-linking reagent is SMPT, which is a bifunctional cross-linker containing a disulfide bond that is "sterically hindered" by an adjacent benzene ring and methyl groups. It is believed that steric hindrance of the disulfide bond serves a function of protecting the bond from attack by thiolate anions such as glutathione which can be present in tissues and blood,  
20 and thereby help in preventing decoupling of the conjugate prior to its delivery to the site of action by the binding agent. The SMPT cross-linking reagent, as with many other known cross-linking reagents, lends the ability to cross-link functional groups such as the SH of cysteine or primary amines (e.g., the epsilon amino group of lysine). Another possible type of cross-linker includes



the heterobifunctional photoreactive phenylazides containing a cleavable disulfide bond such as sulfosuccinimidyl-2-(p-azido salicylamido) ethyl-1,3'-dithiopropionate. The N-hydroxy-succinimidyl group reacts with primary amino groups and the phenylazide (upon photolysis) reacts non-selectively with any amino acid residue.

Although the "hindered" cross-linkers will generally be preferred in the practice of the invention, non-hindered linkers can be employed and advantages in accordance herewith nevertheless realized. Other useful cross-linkers, not considered to contain or generate a protected disulfide, include SATA, SPDP and 2-iminothiolane (Thorpe et al., *Cancer Res* 47:5924-5931 (1987)). The use of such cross-linkers is well understood in the art.

Once conjugated, it will be important to purify the conjugate so as to remove contaminants such as unconjugated toxin or targeting agent. It is important to remove unconjugated targeting agent to reduce undesired toxicity and to avoid the possibility of competition for the antigen between conjugated and unconjugated species. In general, the most preferred purification technique will incorporate the use of Blue-Sepharose with a gel filtration or gel permeation step. Blue-Sepharose is a column matrix composed of Cibacron Blue 3GA and agarose, which has been found to be useful in the purification of immunoconjugates (Knowles & Thorpe, *Anal. Biochem* 120:440-443 (1987)). The use of Blue-Sepharose combines the properties of ion exchange with toxin binding to provide good separation of conjugated toxin from non-conjugated toxin. The Blue-Sepharose column allows the elimination of the free (non-conjugated) targeting agent (e.g., the antibody or fragment) from the

conjugate preparation. To eliminate the free (non-conjugated) toxin a molecular exclusion chromatography step is preferred using either conventional gel filtration procedure or high performance liquid chromatography.

Standard recombinant DNA techniques that are well known to those of skill in the art can be utilized to express nucleic acids encoding the targeting agent/toxin compounds of the invention. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. DNA and RNA synthesis can, additionally, be performed using an automated synthesizers (see, for example, the techniques described in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1989); and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, New York (1989).

When produced via recombinant DNA techniques such as those described herein, the targeting agent/toxin compounds of the invention can be referred to herein as "fusion proteins". It is to be understood that such fusion proteins contain at least a targeting agent and a toxic moiety operatively attached, such that the fusion protein can be used in accordance with the methods of the present invention. The fusion proteins can also include additional peptide sequences, such as peptide spacers which operatively attach the targeting agent and toxin compound, as long as such additional sequences do not appreciably affect the targeting or toxin activities of the fusion protein.

Depending on the specific toxin compound used as part of the fusion protein, it can be necessary to provide a peptide spacer operatively attaching the targeting agent and the toxin compound which is capable of folding into a disulfide-bonded loop structure. Proteolytic cleavage within the loop would then yield a heterodimeric polypeptide wherein the targeting agent and the toxin compound are linked by only a single disulfide bond. See e.g., Lord et al., In *Genetically Engineered Toxins* (Ed. A. Frank, M. Dekker Publ., p. 183) (1992). An example of such a toxin is a Ricin A-chain toxin.

When certain other toxin compounds are utilized, a non-cleavable peptide spacer can be provided to operatively attach the targeting agent and the toxin compound of the fusion protein. Toxins which can be used in conjunction with non-cleavable peptide spacers are those which can, themselves, be converted by proteolytic cleavage, into a cytotoxic disulfide-bonded form (see e.g., Ogata et al., *J Biol Chem* 256:20678-20685 (1990)). An example of such a toxin compound is a Pseudomonas exotoxin compound.

Nucleic acids that can be utilized herein comprise nucleic acid sequences that encode a targeting agent of interest and nucleic acid sequences that encode a toxin agent of interest. Such target agent-encoding and toxin agent-encoding nucleic acid sequences are attached in a manner such that translation of the nucleic acid yields the targeting agent/toxin compounds of the invention.

Standard techniques, such as those described above can be used to construct expression vectors containing the above-described nucleic acids and appropriate transcriptional/translational control sequences. A variety of host-

expression vector systems can be utilized. These include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing targeting agent/toxin coding sequences; yeast (e.g., 5 Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing targeting agent/toxin coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the targeting agent/toxin coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic 10 virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the targeting agent/toxin coding sequences coding sequence; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., 15 metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter; lentiviral vectors).

In bacterial systems a number of expression vectors can be advantageously selected depending upon the use intended for the targeting agent/toxin compound being expressed. For example, when large quantities 20 of targeting agent/toxin compound are to be produced for the generation of antibodies or to screen peptide libraries, vectors which direct the expression of high levels of fusion protein products that are readily purified can be desirable. Such vectors include but are not limited to the E. coli expression vector pUR278 (Ruther et al., *EMBO J* 2:1791 (1983)), in which the targeting

agent/toxin coding sequence can be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein additionally containing a portion of the lac Z product is provided; pIN vectors (Inouye et al., *Nucleic Acids Res* 13:3101-3109 (1985); Van Heeke et al., *J Biol Chem* 5 264:5503-5509 (1989)); and the like. pGEX vectors can also be used to express foreign polypeptides, such as the targeting agent/toxin compounds as fusion proteins additionally containing glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the 10 presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the targeting agent/toxin protein of the fusion protein can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhidrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in 15 *Spodoptera frugiperda* cells. The targeting agent/toxin coding sequences can be cloned into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of the targeting agent/toxin coding sequences will result in inactivation of the polyhedrin gene and production of 20 non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed (see e.g., Smith et al., *J Virol* 46:584 (1983); U.S. Pat. No. 4,215,051).

In mammalian host cells, a number of viral based expression systems can be utilized. In cases where an adenovirus is used as an expression vector, the targeting agent/toxin coding sequences can be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene can then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing targeting agent/toxin proteins in infected hosts (see e.g., Logan et al., *Proc Natl Acad Sci USA* 81:3655-3659 (1984)).

Specific initiation signals can also be required for efficient translation of inserted targeting agent/toxin coding sequences. These signals include the ATG initiation codon and adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, can additionally need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., *Methods in Enzymol* 153:516-544 (1987)).

In addition, a host cell strain can be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation)

and processing (e.g., cleavage) of protein products can be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins. Appropriate cells lines or host systems can be chosen to ensure the correct

5 modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product can be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, etc. For

10 long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express constructs encoding the targeting agent/toxin compounds can be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with targeting agent/toxin DNA controlled by appropriate

15 expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of foreign DNA, engineered cells can be allowed to grow for one or two (1-2) days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers

20 resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.

A number of selection systems can be used, including, but not limited, to the herpes simplex virus thymidine kinase (Wigler et al., *Cell* 11:223 (1977)),

hypoxanthine-guanine phosphoribosyltransferase (Szybalska et al., *Proc Natl Acad Sci USA* 48:2026 (1962)), and adenine phosphoribosyltransferase genes (Lowy et al., *Cell* 22:817 (1980)) can be employed in tk-, hgp<sup>rt</sup>- or ap<sup>rt</sup>-cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler et al., *Proc Natl Acad Sci USA* 77:3567 (1980); O'Hare et al., *Proc Natl Acad Sci USA* 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan et al., *Proc Natl Acad Sci USA* 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al., *J Mol Biol* 150:1 (1981)); and hyg<sup>r</sup>, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147 (1984)).

After a sufficiently purified compound has been prepared, one will desire to prepare it into a pharmaceutical composition that can be administered parenterally. This is done by using for the last purification step a medium with a suitable pharmaceutical composition.

Suitable pharmaceutical compositions in accordance with the invention will generally comprise from about 10 to about 100 mg of the desired conjugate admixed with an acceptable pharmaceutical diluent or excipient, such as a sterile aqueous solution, to give a final concentration of about 0.25 to about 2.5 mg/mL with respect to the conjugate. Such formulations will typically include buffers such as phosphate buffered saline (PBS), or additional additives such as pharmaceutical excipients, stabilizing agents such as BSA or HSA, or salts such as sodium chloride. For parenteral administration it is generally desirable to further render such compositions pharmaceutically acceptable by insuring



their sterility, non-immunogenicity and non-pyrogenicity. Such techniques are generally well known in the art as exemplified by *Remington's Pharmaceutical Sciences*, 16th Ed. Mack Publishing Company (1980), incorporated herein by reference. It should be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less than 0.5 ng/mg protein. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological Standards.

A preferred parenteral formulation of the targeting agent/toxin compounds, including immunotoxins, in accordance with the present invention is 0.25 to 2.5 mg conjugate/mL in 0.15M NaCl aqueous solution at pH 7.5 to 9.0. The preparations can be stored frozen at -10° C to -70° C for at least one (1) year.

#### G. Attachment of Other Agents to Targeting Agents

It is contemplated that most therapeutic applications of the present invention will involve the targeting of a toxin moiety to the endothelium, particularly tumor endothelium. This is due to the much greater ability of most toxins to deliver a cell killing effect as compared to other potential agents. However, there can be circumstances, such as when the target antigen does not internalize by a route consistent with efficient intoxication by targeting agent/toxin compounds, such as immunotoxins, where one will desire to target chemotherapeutic agents such as antitumor drugs, other cytokines, antimetabolites, alkylating agents, hormones, and the like. The advantages of

these agents over their non-targeting agent conjugated counterparts is the added selectivity afforded by the targeting agent, such as an antibody. Exemplary agents include, but are not limited to, such as steroids, cytosine arabinoside, methotrexate, aminopterin, anthracyclines, mitomycin C, vinca  
5 alkaloids, demecolcine, etoposide, mithramycin, and the like. This list is, of course, merely exemplary in that the technology for attaching pharmaceutical agents to targeting agents, such as antibodies, for specific delivery to tissues is well established.

It is proposed that particular benefits can be achieved through the  
10 application of the invention to tumor imaging. Imaging of the tumor vasculature is believed to provide a major advantage when compared to present imaging techniques, in that the cells are readily accessible. Moreover, the technology for attaching paramagnetic, radioactive and even fluorogenic ions to targeting agents, such as antibodies, is well established. Many of these methods involve  
15 the use of a metal chelate complex employing, for example, an organic chelating agent such a DTPA attached to the antibody. See e.g., U.S. Pat. No. 4,472,509. In the context of the present invention the selected ion is thus targeted to the tumor endothelium by the targeting agent, such as an antibody, allowing imaging to proceed by means of the attached ion.

20 A variety of chemotherapeutic and other pharmacologic agents have now been successfully conjugated to antibodies and shown to function pharmacologically (see e.g., Vaickus et al., *Cancer Invest* 9:195-209 (1991)). Exemplary antineoplastic agents that have been investigated include doxorubicin, daunomycin, methotrexate, vinblastine, and various others.

Dillman et al., *Antibody Immunocon Radiopharm* 1:65-77 (1988); Pietersz et al., *Antibody Immunoconj Radiopharm* 1:79-103 (1988). Moreover, the attachment of other agents such as neocarzinostatin (Kimura et al., *Immunogenetics* 11:373-381 (1980)), macromycin, trenimon (Ghose et al., *Meth. Enzymology* 93:280-333 (1983)) and  $\alpha$ -amanitin has been described.

In addition to chemotherapeutic agents, the invention is contemplated to be applicable to the specific delivery of a wide variety of other agents to tumor vasculature. For example, under certain circumstances, one can desire to deliver a coagulant such as Russell's Viper Venom, activated Factor IX, activated Factor X or thrombin to the tumor vasculature. This will result in coagulation of the tumor's blood supply. One can also envisage targeting a cell surface lytic agent such as phospholipase C, (Flickinger & Trost, *Eu. J. Cancer* 12(2):159-60 (1976)) or cobra venom factor (CVF) (Vogel & Muller-Eberhard, *Anal. Biochem* 118(2):262-268 (1981)) which should lyse the tumor endothelial cells directly. The operative attachment of such structures to targeting agents, such as antibodies, can be readily accomplished, for example, by protein-protein coupling agents such as SMPT. Moreover, one can desire to target growth factors, other cytokines or even bacterial endotoxin or the lipid A moiety of bacterial endotoxin to a selected cell type, in order, e.g., to achieve modulation of cytokine release. The attachment of such substances is again well within the skill in the art as exemplified by Ghose et al., *CRC Critical Reviews in Therapeutic Drug Carrier Systems* 3:262-359 (1987).

Thus, it is generally believed to be possible to conjugate to antibodies any pharmacologic agent that has a primary or secondary amine group,

hydrazide or hydrazine group, carboxyl alcohol, phosphate, or alkylating group available for binding or cross-linking to the amino acids or carbohydrate groups of the antibody. In the case of protein structures, this is most readily achieved by means of a cross linking agent as described above. In the case of  
5 doxorubicin and daunomycin, attachment can be achieved by means of an acid labile acyl hydrazone or cis aconityl linkage between the drug and the antibody. Finally, in the case of methotrexate or aminopterin, attachment is achieved through a peptide spacer such as L-Leu-L-Ala-L-Leu-L-Ala, between the  $\gamma$ -carboxyl group of the drug and an amino acid of the antibody.

10 Alternatively, any such structures which are nucleic acid-encoded structures can be operatively attached to the targeting agents of the invention by standard recombinant DNA techniques, such as, for example, those discussed above.

### EXAMPLES

15 The following Examples have been included to illustrate preferred modes of the invention. Certain aspects of the following Examples are described in terms of techniques and procedures found or contemplated by the present inventors to work well in the practice of the invention. These Examples are exemplified through the use of standard laboratory practices of the  
20 inventors. In light of the present disclosure and the general level of skill in the art, those of skill will appreciate that the following Examples are intended to be exemplary only and that numerous changes, modifications and alterations can be employed without departing from the spirit and scope of the invention.

### EXAMPLE 1

#### Endothelial Localization of Receptor Tyrosine Phosphatase, ECRT/DEP-1,

##### In Developing and Mature Renal Vasculature

Developmental assembly of the renal microvasculature is a precise  
5 process requiring spatially and temporally coordinated migration, assembly,  
differentiation and maturation of endothelial cells in the context of adjacent  
epithelial and mesangial cells. Molecular determinants of assembly are largely  
undefined, yet requirements for cell surface receptors to direct context  
appropriate endothelial responses are anticipated. Endothelial expression and  
10 distribution of the receptor tyrosine phosphatase, ECRT/DEP-1, were  
evaluated during developmental assembly of the renal microvasculature.  
Monoclonal antibodies generated against ECRT/DEP-1 ectodomain epitopes  
localize its expression to membrane surfaces of endothelial cells in glomerular,  
peritubular capillary and arterial renal circulations of mature human and murine  
15 kidney. During kidney development, ECRT/DEP-1 immunostaining is evident  
on a subpopulation of metanephric mesenchymal cells and on putative  
progenitors of glomerular capillary endothelial cells early in their recruitment to  
developing glomeruli. ECRT/DEP-1 is prominently displayed on luminal  
membrane surfaces with punctate accumulations at inter-endothelial contacts  
20 that overlap, but do not co-localize with VE cadherin. In vitro studies show that  
ECRT/DEP-1 is recruited to positions of inter-endothelial contact in confluent  
cultured human renal and dermal microvascular endothelial cells, where its  
distribution overlaps, but again does not coincide with VE cadherin.  
Experimental dissociation of VE cadherin from endothelial junctional complexes

does not redistribute ECRT/DEP-1 away from inter-endothelial contacts. These findings indicate that ECRT/DEP-1 ectodomains interact with proteins that are expressed on surfaces of endothelial cells and that are engaged by cell-cell contact, to convey signals for cell recognition, or arrest of migration or proliferation.

In order to identify receptor tyrosine phosphatases expressed in human renal microvascular endothelial cells (HRMEC), degenerate oligonucleotide primers derived from conserved phosphatase domains were used to amplify and sequence cDNAs representing expressed messages, according to methods described in Schoeckmann et al., *J Am Soc Nephrol* 5:730 (1994)(abstract). Among putative receptor cDNAs identified was one that was designated ECRT (endothelial cell receptor tyrosine phosphatase), a product virtually identical to the DEP-1 (for density enhanced phosphatase) cDNA cloned by Ostman et al. from HeLa cells and regulated in abundance by cell density in WI-38 cells. Ostman et al., *Proc Natl Acad Sci USA* 91:9680-9684 (1994). ECRT/DEP-1 (also called byp-1, HPTPh, and CD148) expression has been identified in neonatal smooth muscle cells, in breast and thyroid cancer cell lines, and in all hematopoietic lineages. Keane et al., *Cancer Research* 56:4236-4243 (1996); de la Fuente-Garcia et al., *Blood* 91:2800-2809 (1998). Although ECRT/DEP-1 expression was identified in arterial endothelial cells of the kidney, *in situ* hybridization experiments failed to detect glomerular capillary localization of ECRT/DEP-1mRNA. Borges et al., *Circulation Research* 79:570-580 (1996). The developmental timing and distribution of its expression have not been previously reported.

Like other members of the Class III receptor tyrosine phosphatase family, including GLEPP-1, SAP-1, and DPTP 10D, EC RTP/DEP-1 is a type I membrane protein characterized by a large extracellular domain containing eight or more fibronectin type III repeats and a single cytoplasmic domain phosphatase catalytic domain. Ostman et al., *Proc Natl Acad Sci USA* 91:9680-9684 (1994). The GLEPP-1 receptor tyrosine phosphatase is structurally similar to EC RTP/DEP-1, yet shows renal expression limited to glomerular visceral epithelial cells, where it has been implicated in podocyte integrity. Thomas et al., *J Biol Chem* 269:19953-19962 (1994). Unlike the MAM domain containing receptors, PTP  $\mu$   $\kappa$  and  $\lambda$ , available data do not support participation of class III receptors in homophilic binding, and ligands have not yet been identified.

Monoclonal antibodies were developed against EC RTP/DEP-1 ectodomain epitopes to characterize its distribution in the renal circulation of mature and developing kidney. EC RTP/DEP-1 is expressed at high levels in glomerular, peritubular and renal arterial endothelial cells and shows a pattern of distribution in vivo and in vitro that suggests it contributes to cell-cell recognition required for capillary assembly and maintenance.

#### METHODS

Cell lines and cell culture - Primary human renal microvascular endothelial cells (HRMEC) were isolated, cultured, and used at third or fourth passage after thawing, as described. Martin et al., *In Vitro Cell Dev Biol* 33:261-269 (1997). Human dermal microvascular endothelial cells (HMEC-1 cells, CDC) were grown in MCDB131 media (Sigma Chemical Co. of St. Louis,

Missouri) containing 15% fetal bovine serum (Hyclone Laboratories, Logan Utah, USA), 10 ng/ml epidermal growth factor (Collaborative Biomedical Products, Becton Dickinson, Bedford, Massachusetts), and 1mg/ml hydrocortisone (Sigma Chemical Co. of St. Louis, Missouri) Ades et al., *J Invest Dermatol.* 99:683-690 (1992). Madin Darby Canine Kidney (MDCK) cells (kindly provided by L. Limbird, Vanderbilt Pharmacology) were grown in Dulbecco's minimal essential medium (DMEM, GIBCO BRL, Rockville, Maryland) containing 4.5% D-glucose and supplemented with 10% fetal bovine serum. All growth medium was supplemented with 1mM L-glutamine (GIBCO BRL, Rockville, Maryland), 100 units/ml penicillin and 100mg/ml streptomycin (GIBCO BRL, Rockville, Maryland).

Generation of antibodies to recombinant ECRT/DEP-1 proteins - Ectodomain (amino acids 175-536) and catalytic domain (amino acids 1048-1338) sequences of human, ECRT/DEP-1. Ostman et al., *Proc Natl Acad Sci USA* 91:9680-9684 (1994), were subcloned into the pRSET vector (Invitrogen, Carlsbad, California). Recombinant fusion proteins were expressed in bacteria, purified by a kit sold under the registered trademark NI-AGAROSE AFFINITY™ by Invitrogen of Carlsbad, California, and characterized by SDS-PAGE as greater than 95% homogeneous proteins of 40 and 36 kDa, respectively. Mouse hybridoma antibodies (ECRT-Ab1, ECRT-Ab2) were generated against ECRT/DEP-1 ectodomain (ECRT/DEP-1<sub>ec</sub>) protein by intra-peritoneal immunization, fusion with SP2-0 cells, ELISA screening, selection, expansion and purification by affinity chromatography on PROTEIN A-AGAROSE (Sigma Chemical Co. of St. Louis, Missouri).



Immunodetection of exogeneously expressed ECRT/DEP-1 - MDCK

cells grown in 100mm plastic dishes (sold under the registered trademark FALCON® by Becton, Dickinson and Company, Franklin Lakes, New Jersey) were transfected with an expression plasmid pSRa DEP-1/3xHA that drives

5 high level expression of the human ECRT/DEP-1receptor modified by addition of three repeats of a hemagglutinin peptide (HA) to the carboxy terminus, using cationic lipid (LIPOFECTAMINE™, GIBCO BRL, Rockville, Maryland) according to the manufacturer's protocol. Forty eight hours after transfection, cells were placed on ice, washed twice with ice cold PBS(-) and

10 immediately lysed in 0.5ml lysis buffer (50mM HEPES pH 7.5, 50mM NaCl, 5mM EDTA, 2 µg/mL aprotinin, 1 µg/mL leupeptin, 1mM PMSF). Lysates were clarified by centrifugation, and membrane receptors were recovered by batch adsorption to WGA-Agarose (Sigma Chemical Co. of St. Louis, Missouri) for 4 hours at 4°C. The resultant precipitates were resolved by 7% SDS-PAGE

15 under reducing conditions, transferred to Immobilon-P transfer membranes (Millipore Corporation, Bedford, Massachusetts), and blocked in 5% non-fat dry milk in Tris-buffered saline (50mM Tris HCl pH 7.5, 137 mM NaCl) containing 0.2% Tween 20 (TBST) overnight at 4°C. Blots were incubated with murine monoclonal ECRT/DEP-1 antibodies 1 or 2 (10 µg/mL) or anti-HA (2.5 µg/mL)

20 antibody followed by incubation with horseradish peroxidase-conjugated rabbit anti-mouse IgG antibody (Boehringer Mannheim, Indianapolis, Indiana). Membranes were washed with TBST, then developed using a chemiluminescent substrate (ECL, Amersham, Buckinghamshire, England) according to the manufacturer's instructions.

Generation of Stably Transfected MDCK Cells and Cell Staining -

MDCK cells were transfected with an expression plasmid pCDNA3 DEP-1/3xHA (Invitrogen) using cationic lipids (Lipofectamine™, GIBCO BRL, Rockville, Maryland) according to the manufacturer's protocol. Stable

5 transfectants were selected by addition of G418 (GIBCO BRL, Rockville, Maryland) to culture media at a final concentration of 800 µg/mL, and a single colony was obtained by limited dilution cloning. The cells were grown on glass coverslips (Fisher Scientific, Pittsburgh, Pennsylvania) and fixed with 100% methanol for 10 min at -20°C. Coverslips were washed with phosphate

10 buffered saline, blocked with 5% goat serum for 30 min at room temperature, incubated with ECRTAb-2 (10 µg/mL) for 60 min, washed, then incubated with FITC conjugated goat anti- mouse IgG (Jackson Immunoresearch Laboratory, Westgrove, Pennsylvania) for 60 min. Coverslips were mounted and analyzed by confocal microscopy (equipment sold under the registered

15 trademark ZEISS® LSM410™ by Zeiss, Oberkochen, Germany). To preabsorb the immunoreactivity of ECRTp/DEP-1-Ab, 50 µg of ECRTp/DEP-1 proteins (Ec or Cy) were preincubated with ECRTAb-2 for 4 hours at 4°C, microcentrifuged at 15,000 rpm for 20 min and the resultant supernatant was used to stain cells.

Tissue immunolocalization - Human kidney tissue was snap-frozen in

20 a dry ice-acetone bath. Cryostat sections (4mm) were fixed in acetone at -20°C for 10 min, washed with phosphate buffered saline, and pre-adsorbed with avidin-biotin blocking reagents (Vector Laboratories, Inc. of Burlingame, California) according to manufacturer's instructions. Sections were washed with

phosphate buffered saline, blocked with 5% goat serum, incubated with monoclonal EC RTP/DEP-1 antibody (EC RTP-Ab1, 10 µg/mL, 10 min), washed, incubated with biotinylated goat anti-mouse IgG (Vector Laboratories, Inc. of Burlingame, California, 7.5 µg/mL, 60 min), washed, incubated with fluorescein isothiocyanate (FITC)-conjugated streptavidin (Pierce Chemical Company of Rockford, Illinois, 4 µg/ml, 30 min) and finally washed with phosphate buffered saline. Coverslips were mounted (sold under the trademark Vectashield™ by Vector Laboratories, Inc. of Burlingame, California) and analyzed by confocal microscopy (equipment sold under the registered trademark ZEISS® LSM410™ by Zeiss, Oberkochen, Germany). For colocalization experiments, acetone fixed frozen sections were blocked with 5% donkey serum, and incubated with mixture of EC RTP/DEP-1 antibody (10 µg/mL) and goat VE cadherin antibody (5 µg/mL, Santa Cruz Biotechnology Inc., Santa Cruz, California) at room temperature for 60 minutes. Specific antibodies were detected using a mixture of FITC-conjugated donkey anti-mouse and rhodamine conjugated donkey anti-goat antibodies (Jackson ImmunoResearch Laboratory, Westgrove, Pennsylvania) at room temperature for 60 minutes. Specific immunostaining for each antigen was identified in overlapping images generated by analysis of the same section at 488 nm and 568 nm wavelengths, respectively, on a ZEISS® LSM410™ confocal microscope.

Immunolabeled murine kidney sections showed high background and required an alternative technique. The anti-EC RTP/DEP-1 mAb, EC RTP-Ab1, was directly coupled to FITC. Briefly, EC RTP-Ab1 (0.55 mL of 0.94 mg IgG/mL in 0.1M sodium carbonate buffer, pH 9.0) was conjugated to 0.03 mL FITC

solution (Sigma Chemical Co. of St. Louis, Missouri, 1.0 mg/ml in DMSO) overnight at 4°C. The reaction was stopped by adding ammonium chloride to 50 mM final concentration. Following incubation for 2 hours at 4°C, the mixture was dialyzed exhaustively against phosphate buffered saline to remove unbound FITC. A mouse monoclonal IgG against rat glomerular basement membrane coupled to FITC using the identical protocol was used as a control. Hyink et al., *Am J Physiol* 270:F886-F899 (1996). Acetone fixed sections were blocked with 0.5M ammonium chloride, incubated for 30 min with MoAb-FITC conjugates, washed, and examined by epifluorescence microscopy. In some additional control experiments, the anti-DEP-FITC conjugate was mixed with a molar excess of the immunization peptide before incubation with the sections.

#### Immunoblots and immunocytochemistry of human endothelial cell lines

Human endothelial cells grown in 60 mm dishes were lysed at confluency in 0.5 mL of lysis buffer (20mM TrisCl pH7.5, 50mM NaCl, 1mM EDTA, 0.5% Triton X-100, 0.5% SDS, 0.5% deoxycholate, 2 µg/mL aprotinin, 1 µg/mL leupeptin, 1mM phenylmethylsulfonylfluoride) on ice for 30 minutes. Cleared lysate protein, 150 µg, was incubated with 10 µg/mL of affinity purified rabbit EC RTP/DEP-1 antibody or rabbit IgG (Sigma Chemical Co. of St. Louis, Missouri) at 4°C for 4 hours, and immunoprecipitates were recovered using Protein-a Sepharose (Sigma Chemical Co. of St. Louis, Missouri). SDS-PAGE, and immunoblotting procedures were carried out as described above. Endothelial cells were grown on uncoated glass coverslips (Fisher Scientific, Pittsburgh, Pennsylvania), then fixed with 50% methanol for 10 min at 4°C.

Coverslips were washed with PBS, blocked with 5% goat serum for 30 min at room temperature, incubated with ECRTAb-2 monoclonal antibody (10 µg/ml) or VE cadherin monoclonal antibody (2 µg/mL, BD Transduction Laboratory, Lexington, Kentucky) for 60 min, washed, then incubated with biotinylated goat anti-mouse IgG (Vector Laboratories of Burlingame, California) for 60 min, washed, and finally incubated with fluorescein conjugated (FITC) streptavidin (4 µg/ml, Pierce Chemical Company of Rockford, Illinois) for 30 min. Coverslips were mounted and analyzed by confocal microscopy (equipment sold under the registered trademark ZEISS® LSM410™ by Zeiss, Oberkochen, Germany).

Calcium chelation to disrupt inter-endothelial cadherin complexes -

Confluent HMEC-1 cells grown on glass coverslips in DMEM media supplemented with 15% fetal bovine serum were exposed to addition of EGTA (ethylene glycol-bis(b-aminoethylether)-N,N,N',N'-tetraacetic acid, Sigma Chemical Co. of St. Louis, Missouri) to reach a final concentration of 5mM. Cells were incubated for an additional 20 min, then fixed with 50% methanol at 4°C for 10 min, washed with phosphate buffered saline, and stained with monoclonal ECRTp/DEP-1 antibody (10 µg/ml) or VE cadherin monoclonal antibody (2 µg/mL, BD Transduction Laboratory, Lexington, Kentucky), as described above.

RESULTS - Monoclonal antibodies recognize recombinant and expressed ECRTp/DEP-1. Recombinant fusion proteins representing either ectodomain (Ec) or cytoplasmic domain (Cy) ECRTp/DEP-1 sequences were expressed in bacteria and used to immunize rabbits and/or mice. Shown in

Figure 1A, monoclonal antibodies, ECRTAb-1 and ECRTAb-2, specifically identify the ectodomain but not the cytoplasmic domain recombinant proteins. To ascertain whether these antibodies recognize the full length protein expressed in mammalian cells, MDCK cells were transiently transfected with either an empty expression plasmid (SRa) or one driving expression of a full length ECRT/DEP-1 tagged on the carboxy terminus with a hemagglutinin epitope (SRa DEP-1/HA). Cell lysates from transfected cells were immunoprecipitated using the epitope-specific monoclonal anti-HA antibody, then probed with the antibodies indicated, including ECRTAb-1 and ECRTAb-2 (Figure 1B). Both recognized the 220 kDa HA-tagged ECRT/DEP-1.

Finally, capacity of the monoclonal antibodies to specifically recognize the ECRT/DEP-1 expressed in intact cells was assessed using MDCK cells stably transfected with ECRT/DEP-1. Indirect epifluorescence staining with ECRTAb-2 localized ECRT/DEP-1 to lateral cell membranes (Figure 1C, Panel a), a finding confirmed in confocal Z plane sections of MDCK cells grown to confluence on permeable membrane supports. Competition with the immunizing peptide (Ec) blocked immunostaining (Figure 1C, Panel c) while the irrelevant cytoplasmic domain fusion peptide (Cy) did not (Figure 1C, Panel d).

ECRT/DEP-1 immunoreactivity localizes to endothelial cells of glomerular capillaries, peritubular capillaries and renal arteries. To determine the distribution of ECRT/DEP-1 in mature mammalian kidney, indirect or direct immunofluorescence staining experiments were conducted on frozen sections from human and mouse sources. Shown in Figure 2, ECRT-Ab2

immunolocalizes EC RTP/DEP-1 expression to arterial, glomerular and peritubular capillaries, and in particular, to the endothelial cells in these sites. Higher magnification frames show predominant EC RTP/DEP-1 labeling along the luminal membranes of endothelial cells, at least in the arterial sites where endothelial membrane definition is most reliable (Figure 3).

The punctate characteristic of the staining in the glomerular microcirculation led to the evaluation of whether EC RTP/DEP-1 was engaged in inter-endothelial junctional complexes. In double labeling studies using EC RTP-Ab1 and VE-cadherin antibodies, some overlap was evident (Figure 3). In addition to the luminal endothelial membrane staining, a regional accumulation of EC RTP/DEP-1 was evident at points of inter-endothelial contact, overlapping, but not limited, to the endothelial junctional complexes that include VE cadherin. Lampugnani et al., *J Cell Biol* 129:203-217 (1995). This pattern was evident in both arterial and peritubular capillaries. In extra-renal sites, capillary and large vessel endothelial cells of brain, lung, liver and spleen was identified and endocardial staining were also apparent.

Based on the prominent EC RTP/DEP-1 expression in vascular endothelium of mature kidney, temporal and spatial expression of this receptor during renal vascular development in mouse embryos was evaluated. Shown in Figure 4, EC RTPAb-1 binds as an antigen, its murine EC RTP/DEP-1, based on its similar pattern of staining is mature murine and human kidneys, and based on the effect of the recombinant human immunogen (Ec) to block staining of the mouse tissue. In developing mouse kidneys at E14, E16, and postnatal day 6, (Figure 4A-C) conjugates of EC RTP-Ab1-FITC displayed a

pattern of immunoreactivity that was strikingly similar to the pattern observed previously using antibodies against the VEGF receptor, *flk-1*, and the EphB1/ephrin-B1 receptor-ligand. Daniel et al., *Kidney Int* 50:S-73-S-81 (1996). Notably, EC RTP-Ab1-FITC bound to endothelial cells of developing glomeruli and microvessels in the fetal kidney cortex. Small but intense foci of bound antibody were observed on isolated cortical mesenchymal cells believed to be angioblasts (Figures 4A & 4B). Within vascular clefts of comma- and S-shaped developing glomeruli, a subpopulation of cells consistent with glomerular endothelial precursors were labeled (Figures 4A & 4B).

Immunolabeling for EC RTP/DEP-1 on sections of neonatal kidney produced a distinct vascular labeling pattern (Figure 4C). Arteriolar, glomerular, and peritubular capillary endothelia all labeled intensely (Figure 3C). Glomerular endothelial cells were also brightly labeled in adult mouse kidney (Figure 4D), as they were in sections of human kidney. Other cells within the immature and mature kidneys did not bind EC RTP-Ab1-FITC, and sections labeled with control monoclonal IgG-FITC conjugates, or mixtures of EC RTP-Ab1-FITC and the immunization peptide (Ec) showed no staining.

Independent immunoblot and immunofluorescence staining experiments using EC RTP-Ab1 showed high level expression in endothelial cells cultured from a range of different vascular sites, including the HRMEC from which it was cloned, a dermal microvascular endothelial cell line, HMEC-1 (Ades et al., *J Invest Dermatol* 99:683-690 (1992); human umbilical vein endothelial cells; and a HUVEC derived cell line, Eahy926 (Bauer et al., *J Cell Physiol* 153:437-449 (1992). Epitopes recognized by this antibody were not detected in non-



endothelial cell lines; including HEK293 cells, glomerular mesangial cells, vascular smooth muscle cells, and P19 embryonic carcinoma cells.

Shown in Figure 5 are patterns of EC RTP/DEP-1 localization in human renal microvascular endothelial cells, HRMEC (Panel A), and human dermal microvascular endothelial cells, HMEC (Panel B). Confluent HRMEC cultures displayed prominent staining with EC RTP-Ab2 at points of inter-endothelial contact. In addition, there were punctate accumulations of apical membrane staining in confocal planes capturing the apical surface (Panel A), but not on the basal membrane surface. Endothelial cells plated at sufficiently low density to be isolated from contact with one another did not show the prominent pattern of cell border staining seen in contacting cells. It should be noted that EC RTP-Ab1 did not demonstrate the inter-endothelial localization seen with EC RTP-Ab2, but stained only the subpopulation of receptors evident on the apical surface.

This apparent accumulation of EC RTP/DEP-1 at sites of endothelial cell-cell contact is consistent with the punctate accumulations of staining seen in intact mature vessels, and suggests that a subpopulation of receptors distribute to points of inter-endothelial contact. Thus, the distribution of EC RTP/DEP-1 was compared with that of VE cadherin. Confocal localization of EC RTP/DEP-1 and VE cadherin immunoreactivity in double labeling experiments of confluent HMEC cultures again showed modest overlap of EC RTP/DEP-1 staining with the VE-cadherin localized in inter-endothelial junctions. Similar patterns of colocalization were seen in double labeled sections of human kidney tissue (Figure 3). Finally, experiments were conducted to ascertain whether the

intercellular accumulation of EC RTP/DEP-1 immunoreactivity required the integrity of VE-cadherin interactions. Shown in Figure 5B, EGTA treatment of the HMEC-1 cells dissociates VE cadherin from the inter-endothelial junctional complexes, but has no apparent effect on EC RTP/DEP-1 localization over the 20-30 minute time period of the experiment. This result suggests that any inter-endothelial junctions that can retain EC RTP/DEP-1 do not require cadherin integrity. Furthermore, these data are consistent with the observations that EC RTP/DEP-1 and VE cadherin overlap, but do not co-localize precisely in intact vessel endothelium (Figure 3).

DISCUSSION - Several of the observations presented here provide

new insights about the EC RTP/DEP-1 tyrosine phosphatase in vascular development and in endothelial cell-cell interactions. The significance of the initial identification of EC RTP/DEP-1 as a transcript expressed in cultured human renal microvascular endothelial cells has been confirmed at several levels. Schoecklmann et al., *J Am Soc Nephrol* 5:730 (1994)(abstract). Cultured HRMEC's express the protein on cell membranes, just as glomerular and peritubular capillaries do in intact kidney tissue. Indeed, capillary and arterial endothelium appear to be the dominant cellular sources of EC RTP/DEP-1 expression in mature human and mouse kidney. In contrast with the previous in situ experiments in rat kidney kidneys, described in Borges et al., *Circulation Research* 79:570-580 (1996), high level expression were found in glomeruli of both mouse and human.

Careful evaluation of the sites of membrane to which EC RTP/DEP-1 distributes has shown prominent apical membrane staining in arterial

endothelium in addition to the inter-endothelial membrane staining that appears responsible for the somewhat granular staining pattern in the glomerular capillaries. The lateral cell membrane distribution of ECRT/DEP-1 in the artificial MDCK epithelial cell system and in contacting cultured HRMEC (Figure 5), led to the formal evaluation of the relationship of lateral ECRT/DEP-1 membrane accumulation with VE cadherin complex integrity. The in situ overlap of ECRT/DEP-1 and VE cadherin immunostaining is modest (Figure 3), and is restricted to very focal regions of inter-endothelial contact in some, but not all junctional complexes. As ECRT/DEP-1 lateral membrane distribution is maintained in cultured endothelial cells in which VE cadherin complexes have been dissociated by calcium chelation, it is concluded that there is neither anatomical co-localization nor functional correlation of ECRT/DEP-1 distribution with maintenance of inter-endothelial complexes. These findings, however, cannot exclude the possibility that lateral ECRT/DEP-1 membrane distribution can function to establish conditions permissive to assembly of inter-endothelial complexes containing VE cadherin.

Alternatively, the lateral membrane distribution can reflect interaction of the ECRT/DEP-1 extracellular domain with a putative ligand expressed on contacting membranes that is capable of redistributing receptors or stabilizing them in ligand-receptor complexes created through juxtacrine engagement. Certainly there is available evidence that membrane associated receptor tyrosine phosphatase activity is increased in cultured cells, including endothelial cells, that are in close contact. Pallen and Tong, *Proc Natl Acad Sci USA* 88:6996-7000 (1991); Batt et al., *J Biol Chem* 273:3408-3414 (1998).

In the culture systems presented in this Example, an increase in EC RTP/DEP-1 activity that correlates with cell density and with cell-density mediated growth arrest has been demonstrated.

5           The apical membrane distribution of EC RTP/DEP-1 in arterial and apparently in capillary endothelium is intriguing, particularly in the context of data showing that platelets and all hematopoietic lineages express the EC RTP/DEP-1. Palou et al., *Immunol Lett* 57:101-103 (1997). Homophilic interactions between EC RTP/DEP-1s of endothelial cells and circulating cells that can encounter them on luminal membranes of intact vessels suggest that  
10       it is likely that regulatory factors, or co-receptors on each of the engaging cells are important in modulating any downstream responses.

          Finally, the data assessing the developmental pattern of EC RTP/DEP-1 expression on cells that contribute to assembly of the glomerular capillary network offers insight about roles for this receptor in this coordinated process.  
15       Receptor tyrosine phosphatases of the EC RTP/DEP-1 subclass, including DPTP10D, have been assigned important roles in the targeting of neurons to correct destinations during development. Desai et al., *Cell* 84:599-609 (1996). Previous reports have identified expression in hematopoietic progenitors, including erythroid, lymphoid and myeloid series lineages. Palou et al.,  
20       *Immunol Lett.* 57:101-103 (1997). With the accumulating evidence that hemangioblasts serve as common precursors of both hematopoietic and vascular endothelial lineages, it now appears that EC RTP/DEP-1 expression is initiated early in the ontogeny of these precursors. Furthermore, it appears

that EC RTP/DEP-1 can function to promote differentiation of erythroid lineage cells that express it. Kumet et al., *J Biol Chem.* 271:30916-30921 (1996).

## EXAMPLE 2

### EC RTP/DEP-1 Mediates Signals for Endothelial Growth Arrest and

5

#### Migration Inhibition

Powerful endogenous inhibitors of angiogenesis, such as thrombospondin, angiostatin and endostatin, inhibit the proliferation and migration of cultured endothelial cells in vitro. Such angiogenesis inhibitory controls appear to signal arrest of endothelial growth and migration by engaging endothelial surface receptors. One of the most powerful growth inhibitory signals for cultured endothelial cells is imposed by cell-cell contact, which is described in the art as "density mediated growth arrest" or "contact mediated growth arrest". High level expression of the receptor tyrosine phosphatase, EC RTP/DEP-1, at inter-endothelial contacts in microvascular and large vessel endothelium of human kidney and other organs is described in Example 1.

In this Example, the EC RTP/DEP-1 has been determined to mediate endothelial growth and migration arrest signals. The EC RTP/DEP-1 is catalytically activated in conjunction with cell-cell contact. Transient overexpression of full length EC RTP/DEP-1 arrests endothelial growth and migration. Bivalent forms of a monoclonal antibody, EC RTPAb-1, that binds the EC RTP/DEP-1 ectodomain inhibits endothelial proliferation and migration, while Fab fragments are inactive. This antibody imposes inhibition on corneal

angiogenic responses in a mouse system. These findings indicate that the EC RTP/DEP-1 signals endothelial growth and migration arrest upon engagement of its ligand on the surfaces of contacting endothelial cells, and that surrogate activators, or modulators, of endothelial growth arrest signals are viable candidates for angiogenesis inhibitors.

## METHODS

Cell Culture - Primary human renal microvascular endothelial cells, HRMEC, were isolated, cultured, and used at third or fourth passage after thawing, as described in Martin et al., *In Vitro Cell Dev Biol* 33:261-269 (1997).

10 Human dermal microvascular endothelial cells (HMEC-1 cells, CDC) were grown in MCDB131 media (Sigma Chemical Co. of St. Louis, Missouri) containing 15% fetal bovine serum (Hyclone Laboratories, Logan Utah, USA), 10 ng/mL epidermal growth factor (Collaborative Biomedical Products; Becton Dickinson, Bedford, Massachusetts), and 1 µg/mL hydrocortisone (Sigma

15 Chemical Co. of St. Louis, Missouri). Ades et al., *J Invest Dermatol* 99:683-690 (1992). All growth media were supplemented with 1mM L-glutamine (GIBCO BRL, Rockville, Maryland), 100 units/mL penicillin and 100 µg/mL streptomycin (GIBCO BRL, Rockville, Maryland).

Antibodies - Ectodomain (EC RTP/DEP-1<sub>ect</sub>, amino acids 175-536) and

20 catalytic domain (EC RTP/DEP-1<sub>cat</sub>, amino acids 1048-1338) sequences of human EC RTP/DEP-1 (Ostman et al., *Proc Natl Acad Sci USA* 91:9680-9684 (1994) were subcloned into the pRSET vector (Invitrogen, Carlsbad, California). Recombinant fusion proteins were expressed in bacteria, purified by Ni-agarose affinity (Invitrogen, Carlsbad, California), and characterized by SDS-

PAGE as greater than 95% homogeneous proteins of 40 and 36 kDa, respectively. Rabbit antiserum to the EC RTP/DEP-1<sub>cy</sub> protein was generated by repetitive immunization, and was affinity purified, as described in Koenig et al., *J Clin Immunol* 13:204-211 (1993). Mouse hybridoma antibody EC RTPAb-1 was obtained following immunization with EC RTP/DEP-1<sub>ec</sub> protein by intraperitoneal immunization, fusion with SP2-0 cells, ELISA screening, selection, expansion and purification by affinity chromatography on protein A-agarose (Sigma Chemical Co. of St. Louis, Missouri).

#### Assays for EC RTP/DEP-1 Abundance and Tyrosine Phosphatase

- 10 Activity - Cells plated at the densities and harvested at the times indicated in the Figure Descriptions were washed repeatedly with iced phosphate buffered saline before *in situ* addition of 2 ml of buffer containing 50mM Hepes (pH 7.5), 50mM NaCl, 5mM EDTA, 1mM PMSF, 1mM  $\beta$ -mercaptoethanol, 1% Triton X-100. Detergent solubilized cells were incubated for 15 min at 4°C and insoluble material was removed by repeated microcentrifugation (two times) at 13,000 x g, 10 min, 4°C. Proteins in solubilized fractions were quantitated using a modified BCA assay (Pierce Chemical Company of Rockford, Illinois). In some experiments, batch adsorption and elution from *triticum vulgaris* lectin (WGA) conjugated to agarose (Sigma Chemical Co. of St. Louis, Missouri) was conducted as described in Stein et al., *J Biol Chem* 271:23588-23593 (1996). Final elution for fractions subjected to phosphatase assays was in buffer containing 25 mM imidazole (pH 7.2), 0.1 mg/ml bovine albumin, 10mM dithiothreitol (phosphatase assay buffer), plus 3mM N,N',N'' triacetylchitotriose (Sigma Chemical Co. of St. Louis, Missouri).
- 15
- 20

<sup>32</sup>P-labeled, phosphorylated substrate (Raytide) was prepared by the manufacturer's recommendations as described (Oncogene Sciences of Uniondale, New York) to achieve specific activities of (dpm/fmol). Phosphatase activity in lectin purified fractions was assayed in triplicate at 30°C for times indicated in the Figure Descriptions in 200µl volumes of phosphatase buffer using 300 ng/ml substrate in the presence or absence of Na<sub>3</sub>VO<sub>4</sub>, as described. Released phosphate was quantitated by scintillation counting and data are expressed as mean cpm +/- SEM. Assays were linear over 1-10 min periods.

For determination of EC RTP/DEP-1 activity and abundance (Figure 8) HRMEC cells were plated at cell densities indicated in the Figure Descriptions. At 36 hours after plating, a subset of cells, as indicated, was treated for 10 min with pervanadate (1mM H<sub>2</sub>O<sub>2</sub> + 1mM Na<sub>3</sub>VO<sub>4</sub>), then cells were lysed in buffer containing 50mM HEPES/pH7.5, 150mM NaCl, 5mM EDTA, 1% Triton X-100, 0.1mM, 5µg/ml aprotinin, 1 µg/ml leupeptin, 1mM PMSF, clarified by centrifugation and equivalent lysate proteins(150µg) were immunoprecipitated by incubation with affinity-purified monospecific EC RTP/DEP-1 rabbit antibody (12.5 µg/mL) overnight at 4°C, and collected on protein A-sepharose (Sigma Chemical Co. of St. Louis, Missouri).

The washed immunocomplexes were assayed for PTP activity with p-nitrophenylphosphate, pNPP (Sigma Chemical Co. of St. Louis, Missouri) as previously described in Wang, Y. and Pallen, C.J., *J Biol Chem* 267:16696-16702 (1992). Briefly, the immunocomplexes were incubated with reaction mixture (50mM sodium acetate/pH5.5, 0.5mg/mL bovine albumin, 0.5mM DTT, 5mM pNPP) at 30°C for 30 min in the absence or presence of 1mM Na<sub>3</sub>VO<sub>4</sub>.



Reactions were stopped by addition of 2N NaOH, and the absorbance at 410nm was measured.

For quantification of EC RTP/DEP-1 abundance, immunoprecipitated fractions were also resolved by 7% SDS-PAGE under reducing conditions, transferred to PVDF membranes (sold under the trademark Immobilon-P™ by Millipore Corporation, Bedford, Massachusetts), and blocked in 5% non-fat dry milk in Tris-buffered saline (50mM Tris/HCl pH7.5, 137 mM NaCl) containing 0.2% Tween 20 (TBST) overnight at 4°C. Blots were incubated with EC RTPAb1 (10 µg/mL) or phosphotyrosine monoclonal antibody, 4G10, (1.0 µg/mL, Upstate Biotechnology) and bound antibodies detected with horseradish peroxidase-conjugated rabbit anti-mouse IgG antibody (Boehringer) and a chemiluminescent reagent (ECL; Amersham, Buckinghamshire, England).

Proliferation Assays - In initial assays of HRMEC proliferation (Figure 6), cells were plated at the indicated density, harvested at the indicated times and counted in quintuplicate. Data represent means  $\pm$  SEM. In other experiments (Figures 8 and 9), HMEC-1 cells were grown on a 35mm diameter dish (sold under the registered trademark FALCON® by Becton, Dickinson and Company, Franklin Lakes, New Jersey) and cotransfected with EC RTP/DEP-1 expression plasmids (either parent vector, pSR $\alpha$ , or pSR $\alpha$ -EC RTP/DEP-1/3xHA, driving high level expression of a carboxyterminal hemagglutinin (HA) epitope tagged human EC RTP/DEP-1, 1.8µg) and a green fluorescence protein expression plasmid (pEGFP, Clontech, 0.4µg). An adenovirus-assisted lipofectamine procedure that transfects 40-50% of HMEC-1 cells under these conditions was

used, as is also described in Example 1. Transfected cells were harvested 48h after transfection and replated on glass coverslips in individual wells of a 12 well plate at densities indicated in the Figure Descriptions (range  $2-10 \times 10^4$ ), to achieve attached cell confluencies of 20-90+%). Proliferating cells were labeled by addition of  $10\mu\text{M}$  5-Bromo-2'-deoxy-uridine (BrdU) to culture media for 30 min at 70 hours after transfection. BrdU incorporation was immunocytochemically detected using a monoclonal BrdU antibody and rhodamine-conjugated anti-mouse IgG, according to manufacturer's protocol (Boehringer Mannheim, Indianapolis, Indiana). The cells of at least five independent fields were observed under epifluorescence microscopy (Nikon ECLIPSE® E600™) and the frequency of BrdU labeling in GFP positive cells was scored.

Planar Endothelial Migration Assay - A planar endothelial migration assay was developed to assess the rate of endothelial closure of circular "wounds" of 300-500 $\mu$  diameter. A rotating silicon-tipped bit attached to a drill press was used to generate 3-5 "wounds" in confluent endothelial monolayers within individual wells of multi-well plates. At the time of "wounding", medium in individual wells were supplemented with agents at concentrations indicated in the Figure Descriptions. Residual areas of individual wounds in photomicroscopic images captured at the indicated times (4 & 8 hours) were quantitated using a Bioquant (Nashville, Tennessee) software package calibrated to a Nikon DIAPHOT® microscope. Expressed in this manner, the rates of wound closure are remarkably linear, with linear regression  $r^2$  values  $\geq 0.985$ . Each data point displayed here represent the mean  $\pm$  SEM of three

or more individual determinations from the same well. Each experiment described is representative of findings from three or more independent observations.

In situ Transfection Assay for Migration - Confluent HMEC-1 cells grown on 6 well culture plate were transfected with 2.2  $\mu$ g of expression plasmids, pSR $\alpha$  ECRTP/DEP-1/3xHA, or pSR $\alpha$ -EphB1/3xHA (Stein et al., *Genes Dev* 12:667-678 (1998)) and circular wounds were prepared at 48 hours after transfection as described above. When the wounds were almost closed (12 h after wounding), monolayers were fixed with 2% paraformaldehyde for 20 min, washed with phosphate buffered saline, permeabilized with 0.02% saponin for 60 min, blocked with 5% goat serum and incubated with 5  $\mu$ g/mL of monoclonal HA antibody, 12CA5, (Berkeley Antibody Company (BAbCo), Richmond, California) for 60 min. Coverslips were then washed with phosphate buffered saline, incubated with biotinylated goat anti-mouse IgG (Vector Laboratories, Inc. of Burlingame, California, 7.5  $\mu$ g/mL) for 60 min, washed, incubated with HRP conjugated avidin-biotin complexes (Vector Laboratories, Inc. of Burlingame, California) for 30 min and finally developed using 6 mg/mL of 3, 3'-diaminobenzidine (Sigma Chemical Co. of St. Louis, Missouri).

Cornea Pocket Angiogenesis Assay - Agents to be tested for angiogenic or anti-angiogenic activity were immobilized in a slow release form in an inert hydron pellet of approximately 0.2  $\mu$ l volume, as described in Kenyon, Voest, et al. (1996). That pellet is implanted into the corneal epithelium of an anesthetized C57BL mice in a pocket created by micro-dissection. Over a 5 to 7 day period angiogenic factors stimulate the ingrowth of vessels from the

adjacent vascularized corneal limbus. A photographic record is generated using slit lamp photography. The appearance, density and extent of these vessels are evaluated and scored. In some cases the time course of the progression is followed in anesthetized animals, prior to sacrifice. Vessels are evaluated for length, density and the radial surface of the limbus from which they emanate (expressed as clock-face hours).

Results - Initial experiments were conducted to establish the cell density (cell number/surface area) at which human renal microvascular endothelial cells (HRMEC) display growth arrest in serum supplemented growth medium. In situ experiments have shown high level expression of ECRT/DEP-1 in glomerular and extraglomerular microvascular endothelial cells of human kidney, as well as in arteries and a wide range of other tissues. In Figure 6A, identical numbers of HRMEC were plated on cell culture plates of 9.6, 28.3, or 78.5 cm<sup>2</sup>, representing 1, 2.9, or 8.1 fold the surface area of a 35mm diameter dish, as indicated. Growth medium was replaced every 3 days. Depending upon passage number, HRMEC reached growth arrest at a density of approximately  $1.3\text{-}6 \times 10^4$  cells/cm<sup>2</sup>, a response that supercedes responses to maximal growth stimuli. Doubling time under density unrestricted conditions is approximately 44 hours. The established human dermal microvascular endothelial cell line, HMEC-1, similarly displayed density-mediated growth arrest properties.

Increasing fibroblast cell density was previously associated with increases in tyrosine phosphatase activity recovered from membrane-associated fractions. See e.g., Pallen, C.J. and Tong, P.H. *Proc Natl Acad Sci*

USA 88:6996-7000 (1991). Among membrane-associated proteins, can surface receptors, including ECRT/DEP-1, are modified by N-linked glycosylation of the ectodomain region and can be recovered using lectin affinity chromatography. Honda et al., *Blood* 84:4186-4194 (1994). Shown in

5 Figure 6B, tyrosine phosphatase activity of the *triticum vulgaris* (wheat germ agglutinin, WGA) lectin fraction recovered from identical numbers of HRMEC plated was analyzed for the indicated times at densities determined by the culture dish surface area. As early as 15 hours after plating, marked differences in vanadate-sensitive tyrosine phosphatase activity were evident.

10 Lectin-recovered receptor-associated tyrosine phosphatase activity was 2 fold higher in cells plated at a density sufficient to impose growth arrest (8.1x), compared with those plated at lower density (1x). As cells plated at lower densities (2.9 and 1x) proliferated, increases in activity were seen, eliminating the marked difference. The increased lectin-recovered activity was evident at

15 times anticipating the imposition of proliferation arrest, suggesting that either the prevalence of specific tyrosine phosphatases was increasing, that the activity of pre-existing phosphatases was increased, or that tyrosine phosphatases were being recruited to associate with lectin recovered proteins. The previous report that DEP-1 receptor prevalence increased with increasing

20 cell density lead us to evaluate the activity and distribution of DEP-1. Ostman et al., *Proc Natl Acad Sci USA* 91:9680-9684 (1994).

Shown in Figure 7, differences in the amount of immunoprecipitated ECRT/DEP-1 antigen could not be detected when cells plated for 33 hours at different densities were compared. Additional experiments failed to show a

change in the ratio of Triton X-100 soluble to insoluble fractions at these densities. However, 1.8 fold increases in the vanadate-sensitive EC RTP/DEP-1 associated tyrosine phosphatase activity were recovered by immunoprecipitation from cells plated at the highest (8.1x) compared with the lowest (1x) cell density. Shown in the lower panel immunoblot (Figure 7), immunoprecipitated EC RTP/DEP-1 is itself a tyrosine phosphoprotein in cells pretreated with vanadate. Moreover, the level of intrinsic phosphotyrosine is decreased in the immunoprecipitated EC RTP/DEP-1 recovered from cells plated at high density, correlating with the increased tyrosine phosphatase activity in that fraction. These findings indicate that the abundance of EC RTP/DEP-1 does not change acutely in endothelial cells plated at high density, but that the EC RTP/DEP-1-associated phosphatase activity does increase. Efforts to demonstrate by in gel zymographic phosphatase assays that the increased activity is intrinsic to EC RTP/DEP-1 have not been successful.

To further pursue the possibility that EC RTP/DEP-1 mediates signals capable of arresting endothelial proliferation and migration, HMEC-1 cells were cotransfected with an expression plasmid driving high level expression of an epitope-tagged EC RTP/DEP-1, and with a plasmid driving expression of green fluorescent protein to mark transfected cells. Using adenovirus-assisted transfection method, transfection of 40-50% of HMEC-1 cells that display survival, migration and proliferation properties similar to nontransfected cells was routinely accomplished. Shown in Figure 8A, high level expression of a full length EC RTP/DEP-1 imposes marked suppression of BrdU incorporation

across a range of plating densities of transfected cells when compared with the empty expression vector.

ECRTP/DEP-1 overexpression imposed similar effects upon endothelial migration as those observed with proliferation. Shown in Figure 9A, HMEC-1 cells transfected with plasmids driving expression of hemagglutinin epitope (HA) tagged versions of either ECRTP/DEP-1/HA or a receptor tyrosine kinase, EphB1/HA, were plated at densities to permit them to rapidly attain a confluent monolayer. A circular "wound" of approximately 500µm diameter was generated, and migration of transfected and non-transfected cells to close the "wound" was determined after 33 hours, by staining for the expressed protein HA epitope. Unlike cells transfected with the EphB1/HA control, ECRTP/DEP-1/HA expressing cells did not migrate to contribute to the wound closure. While forced overexpression of ECRTP/DEP-1 can be informative about the potential for this receptor to affect proliferation or migration, this approach is much less discriminatory than use of high affinity reagents interacting with endogenously expressed ECRTP/DEP-1s. To this end, a panel of monoclonal antibodies generated against ECRTP/DEP-1 ectodomain sequences was screened for activity.

Shown in Figure 8B, bivalent forms of the monoclonal, ECRTpAb1, imposed a marked inhibitory effect on proliferation of HRMEC plated at low density, in spite of repeated growth medium exchanges. Equivalent concentrations of a class matched monoclonal control antibody were inactive. Because oligomerization is a critical determinant of activation of many receptor tyrosine kinases and phosphatases (Weiss, A. and Schlessinger, J., *Cell*

94:277-280 (1998)), ECRTAb1 Fab fragments were prepared to test whether bivalency of the interacting monoclonal was required for activity. Also shown in Figures 8B and 8C, equimolar concentrations of the ECRTAb1 Fab fragments were inactive as growth inhibitors in endothelial cells plated at subconfluent densities in serum-containing growth medium.

Additional endothelial "wound" closure assays, similar in design to those presented in Figure 9A, were conducted to evaluate effects of bivalent and monovalent ECRTAb1 on endothelial migration. Displayed in Figure 9B are the residual fractions of original wound areas remaining at the times indicated.

10 Phorbol myristate acetate (PMA) markedly accelerated the rate of migration and wound closure, compared with unstimulated cells in serum-free medium. Bivalent ECRTAb1 displayed marked activity to inhibit the PMA stimulated migration, while equimolar concentrations of monovalent Fab fragments, and a control monoclonal were inactive. The linear characteristics of time

15 dependent "wound" closure in this assay permitted us to determine relative migration rates for the population, expressed in Figure 9C as fractional closure/hr. Effective concentrations of bivalent ECRTAb1 (67 and 200 nM) were similar to those active as inhibitors of proliferation (Figure 8C).

In aggregate, these findings suggested that engagement of endogenous

20 ECRTp/DEP-1s by bivalent antibodies can function like a "surrogate ligand" to emulate responses normally evoked by an endogenous membrane-associated ligand upon cell-cell contact. Since the ECRTAb1 Fab fragments were inactive as "surrogate ligands" to inhibit migration and proliferation in subconfluent cells, it was asked whether they can have activity as *antagonists*



of endogenous ligand engagement of EC RTP/DEP-1 in cells plated at high density. It was reasoned that Fab fragments can interrupt endogenous ligand-receptor engagement and subsequent growth arrest signals in cells plated at high density. Shown in Figure 10, EC RTPAb-1 Fab had a marked effect to  
5 release cells from the density-imposed inhibition of BrdU uptake that marks S phase entry.

As a final test to determine whether EC RTPAb-1 functions to induce an angiostatic signal, it was tested whether this antibody modified angiogenic responses to basic FGF in the mouse corneal pocket assay. Shown in Figure  
10 11, inclusion of EC RTPAb-1, but not a control IgG, in the implanted slow release hydon pellet inhibited angiogenesis, scored by reducing the length of capillary sprouts as they approached the source of the angiogenic stimulus. This attenuation of capillary length, without effect on radial distribution of new vessels, suggests that pro-angiogenic basic FGF can diffuse more rapidly from  
15 the slow release pellet than EC RTPAb-1, permitting brisk initiation of angiogenesis with subsequent attenuation.

### EXAMPLE 3

#### Method of Screening for Endogenous Ligand of EC RTP/DEP-1

Labeled EC RTP/DEP-1 is used to perform binding studies to identify  
20 cells with EC RTP/DEP-1 ligands using Scatchard analysis; and to perform cross-linking studies which demonstrate the EC RTP/DEP-1 ligand(s) on polyacrylamide gels. These initial characterization methods are used to identify cells with high and low numbers of EC RTP/DEP-1 ligand(s) for purification and

isolation studies. Once a cell line with high levels of EC RTP/DEP-1 ligand has been identified, then the protein is purified by the following approaches:

Approach A: Biochemical purification

5 A cell line which expresses high levels of EC RTP/DEP-1 ligand is lysed and the protein from lysates or membrane preparations is purified by gel filtration followed by purification of the ligand with a column containing the EC RTP/DEP-1 bound to a solid phase such as sepharose. The purified ligand protein can then be microsequenced and the gene cloned using degenerate oligonucleotides derived from the protein sequence.

10 Approach B: cDNA library purification

The EC RTP/DEP-1 is radiolabeled with  $^{125}\text{I}$  and then used to screen cell lines or tissues by Scratchard analysis for specific binding of ligand. Once such ligand binding is identified, a cDNA library is constructed from that tissue or cell line and transfected into a cell line that does not exhibit specific binding.  
15 These transfected cells are then screened for newly acquired specific binding which indicates they have been transfected with a construct containing the gene for the EC RTP/DEP-1 ligand. Plasmid DNA from positive clones is then isolated and sequenced for identification. A single construct is then transfected back into the null cells to verify that binding between ligand and receptor is  
20 mediated by the transfected gene. Kluzen et al. *Proc Natl Acad Sci USA* 89:4618-4622 (1992).

Alternatively, chimeric EC RTP/DEP-1 and immunoglobulin Fc molecules are constructed. LaRoche et al., *J Cell Biol* 129:357-366 (1995). The chimeric molecules can then be used to screen for binding to EC RTP/DEP-1 ligand on whole cells via flow cytometry. Alternatively, due to the presence of the immunoglobulin component of the molecule, cell lysates are screened by immunoblotting or by immunoprecipitation of metabolically labeled cells. This technique can identify EC RTP/DEP-1 binding proteins by a variety of different methods. Peptide digests of the identified proteins are then generated so that peptides can be sequenced and the whole molecule cloned by the degenerative oligonucleotide approach.

Thus, this Example pertains to a method for isolating a ligand for an EC RTP/DEP-1, and to a purified and isolated ligand for an EC RTP/DEP-1. The method comprises contacting cells or cell lysates having the ligand or suspected of having the ligand with EC RTP/DEP-1; and isolating the ligand which binds with EC RTP/DEP-1. The cells having the ligand are identified by labeling the EC RTP/DEP-1; screening cell cultures with the labeled EC RTP/DEP-1; and isolating cells that bind an elevated amount of the labeled EC RTP/DEP-1.

The ligand is isolated by lysing the cells and passing the cell lysate over a column containing the EC RTP/DEP-1 bound to a solid phase matrix within the column. Alternatively, the ligand is isolated by constructing a cDNA library from the cells binding the ligand; transfecting the cDNA library into a cell line that does not exhibit binding of the ligand; screening the cell line for newly acquired specific binding; isolating DNA from cells exhibiting specific binding;

and sequencing the isolated DNA to determine the DNA sequence for the ligand.

The EC RTP/DEP-1 is optionally labeled by binding the EC RTP/DEP-1 to an immunoglobulin. In this case, the ligand is isolated by immunoprecipitation of the EC RTP/DEP-1-ligand-immunoglobulin complex. Alternatively, the ligand of the EC RTP/DEP-1 is isolated using flow cytometry.

#### EXAMPLE 4

##### Identification of Binding Epitope for EC RTPAb-1

A series of 96 eight to nine amino acid peptides was generated. The eight to nine amino acid peptides span in overlapping epitopes the 351 amino acid sequence against which EC RTPAb-1 was derived was generated. These peptides were generated and immobilized in a defined array on the surface of a membrane that was probed with EC RTPAb-1. Binding of EC RTPAb-1 to peptide #41 in the array was identified using a peroxidase-conjugated anti-mouse IgG second antibody, by chemiluminescence autoradiography (Figure 12). The sequence of this peptide derived from the array is n-QSRNDEVL-c. The 8-amino acid epitope represents the target sequence within the EC RTP ectodomain against which functional EC RTP agonists and antagonists interact, based on biological activities of EC RTPAb-1. Antibodies, including humanized antibodies, and other peptides with high affinity for this defined amino acid sequence have biological activities comparable to those demonstrated herein using EC RTPAb-1.

## EXAMPLE 5

### Assay for Scoring Biological Activity of Antibodies.

#### Proteins and Peptides that Bind ECRTTP

In an effort to develop a simplified reconstitution assay system capable of scoring biological activities mediated through ECRTTP, Chinese Hamster Ovary (CHO) cells that do not express endogenous ECRTTP were transfected with a plasmid construct driving high level expression of ECRTTP (pSR $\alpha$ -ECRTTP/HA), or catalytically inactive mutated forms (pSR $\alpha$ -ECRTTP/HA/C-S, pSR $\alpha$ -ECRTTP/HA $\Delta$ cy), in these cells. Transiently transfected CHO cells were then dispersed and plated on 24 well plates and exposed to either control IgG<sub>1</sub> or ECRTPAb-1, or monovalent forms of ECRTTP (ECRTPAb-1-Fab). Proliferation of cells transfected with wild type ECRTTP, but not with either mutant form, was inhibited (approximately 40%) by incubation with ECRTPAb-1, but not with either control IgG<sub>1</sub> or ECRTPAb-1-Fab.

In parallel, ECRTTP was immunoprecipitated from CHO cells transfected with these plasmids and expressing equivalent amounts of ECRTTP or mutant forms (shown in the inserts above Figures 13A and 13B) following a time course of exposure (0 - 30 min) to either ECRTPAb-1 or ECRTPAb-1-Fab. Shown in the immunoblot panels on the right in Figures 13A and 13B, Ab1 evoked a rapid de-phosphorylation of tyrosine residues on the wild type (WT) ECRTTP, but had no effect on catalytically inactive C/S mutant forms. These findings provide primary evidence that the catalytic phosphatase function is critical to the action of ECRTPAb-1 to inhibit proliferation and to provoke de-phosphorylation of ECRTTP.

Finally, co-expression of either catalytically inactive C/S or Cy deleted forms of ECRTp with the functional ECRTp form abrogates inhibitory effects of the ECRTpAb-1 on CHO proliferation (Figure 13B). This proliferation assay thus evaluates whether putative counter-receptors (ligands) are competent to function through ECRTp to inhibit cell growth. In each case, the monovalent and bivalent forms of ECRTpAb-1 provide a reagent that can be used in the assay to define functional counter-receptors.

#### EXAMPLE 6

##### Transgenic Animal Having Catalytically Inactive ECRTp/DEP-1

A transgenic mouse expressing a catalytically inactive form of ECRTp/DEP-1 was prepared. The mouse was prepared using a "knockout" approach with respect to the ECRTp/DEP-1 gene. Embryonic death was observed in homozygous "knockout" animals. Heterozygous animals displayed significant vascularization malformations. Thus, the transgenic mouse further established the role of ECRTp/DEP-1 in cell growth, cell survival and angiogenesis.

#### REFERENCES

The references listed below as well as all references cited in the specification are incorporated herein by reference to the extent that they supplement, explain, provide a background for or teach methodology, techniques and/or compositions employed herein.

Ades et al., *J Invest Dermatol* 99:683-690 (1992).

- Augenlicht and Baserga, *Exp Cell Res* 89:255-262 (1974).
- Ausprunk et al., *Am J Pathol*, 79:597-618 (1975).
- Batt et al., *J Biol Chem* 273:3408-3414 (1998).
- Bauer et al., *J Cell Physiol* 153:437-449 (1992).
- 5 Beekhuizen, H. and van Furth, R. *J Vascular Res* 31:230-239 (1994).
- Billard, C., et al., *Blood* (2000 Feb 1) 95(3):965-72.
- Bittner et al., *Methods in Enzymol* 153:516-544 (1987).
- Bodanszky, et al., "Peptide Synthesis", John Wiley & Sons, Second Edition, (1976).
- 10 Borges et al., *Circulation Research* 79:570-580 (1996).
- Cheresh et al., *J Biol Chem*, 262:17703-17711 (1987).
- Choime et al., *J Biol Chem* 270:21144-21150 (1995).
- Coomber, B.L. *J Cell Biochem* 52:289-296 (1993).
- Daniel et al., *Kidney Int* 50:S-73-S-81 (1996).
- 15 de la Fuente-Garcia et al., *Blood* 91:2800-2809 (1998).
- Desai et al., *Cell* 84:599-609 (1996).
- Dillman et al., *Antibody Immunocon Radiopharm* 1:65-77 (1988).
- Dulbecco et al., *Virology* 8:396 (1959).
- Eijgenraam, F., *Science* 261:883-884 (1993).
- 20 Engerman et al., *Laboratory Investigation* 17:738-744 (1967).
- EP 44167
- Fields et al., *Int. J. Peptide Protein Res* 35:161-214 (1990).
- Flickinger & Trost, *Eu. J. Cancer* 12(2):159-60 (1976).
- Ghose et al., *CRC Critical Reviews in Therapeutic Drug Carrier*

*Systems* 3:262–359 (1987).

- Ghose et al., *Meth. Enzymology* 93:280–333 (1983).
- Gumkowski et al., *Blood Vessels* 24:11-23 (1987).
- Hailing et al., *Nucl Acids Res* 13:8019–8033 (1985).
- 5 Honda et al., *Blood* 84:4186-4194 (1994).
- Huse et al., *Science* 246:1275–1281 (1989).
- Hyink et al., *Am J Physiol* 270:F886-F899 (1996).
- Inouye et al., *Nucleic Acids Res* 13:3101–3109 (1985).
- Keane et al., *Cancer Research* 56:4236-4243 (1996).
- 10 Kimura et al., *Immunogenetics* 11:373–381 (1980).
- Kitamoto et al., *J Clin Invest* 99:2351-2357 (1997).
- Kluzen et al. *Proc Natl Acad Sci USA* 89:4618-4622 (1992).
- Knowles & Thorpe, *Anal. Biochem* 120:440–443 (1987).
- Koenig et al., *J Clin Immunol* 13:204-211 (1993).
- 15 Kohler and Milstein, *Nature* 256:495–497 (1975).
- Kumet et al., *J Biol Chem* 271:30916-30921 (1996).
- Lamb et al., *Eur Jmol Biochem* 148:265–270 (1985).
- Lampugnani et al., *J Cell Biol* 129:203-217 (1995).
- LaRochelle et al., *J Cell Biol* 129:357-366 (1995).
- 20 Leveen et al., *Genes Dev* 8:1875-1887 (1994).
- Logan et al., *Proc Natl Acad Sci USA* 81:3655–3659 (1984).
- Lord et al., In *Genetically Engineered Toxins* (Ed. A. Frank, M. Dekker Publ.,  
p. 183) (1992)
- Lowy et al., *Cell* 22:817 (1980).



- Martin et al., *In Vitro Cell Dev Biol* 33:261-269 (1997).
- McOmie, J. F. W., "Protective Groups in Organic Chemistry", Plenum Press,  
New York, (1973).
- Meienhofer, J., "Hormonal Proteins and Peptides", Vol. 2, p. 46, Academic  
5 Press (New York) (1983).
- Merrifield, *Adv Enzymol*, 32:221-96 (1969).
- More et al., *J Pathol* 172:287-292 (1994).
- Mulligan et al., *Proc Natl Acad Sci USA* 78:2072 (1981).
- O'Hare et al., *FEBS Lett* 210:731 (1987).
- 10 Ogata et al., *J Biol Chem* 256:20678-20685 (1990).
- Ossonski et al., *Cancer Res* 40:2300-2309 (1980)
- Ostman et al., *Proc Natl Acad Sci USA* 91:9680-9684 (1994).
- Pallen, C.J. and Tong, P.H. *Proc Natl Acad Sci USA* 88:6996-7000 (1991).
- Palou et al., *Immunol Lett* 57:101-103 (1997).
- 15 Pietersz et al., *Antibody, Immunoconj Radiopharm* 1:79-103 (1988).
- Pluckthun, in *The Pharmacology of Monoclonal Antibodies*, vol. 113,  
Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).  
*Remington's Pharmaceutical Sciences*, 16th Ed. Mack Publishing Company,  
(1980)
- 20 Rijksen et al., *J Cell Physiol* 154:393-401(1993).
- Robert et al., *Am J Physiol* 271:F744-F753 (1996).
- Robert et al., *Am J Physiol* 275:F164-F172 (1998).
- Ruther et al., *EMBO J* 2:1791 (1983).
- Sastry, et al., *Proc Natl Acad Sci USA* 86:5728-5732 (1989).

- Schoecklmann et al., *J Am Soc Nephrol* 5:730 (1994) (abstract).
- Scholz et al., *Cell Tissue Res* 290:623-631 (1997).
- Schroder et al., "The Peptides", Vol. 1, Academic Press (New York) (1965).
- Smith et al., *J Virol* 46:584 (1983).
- 5 Soriano, P., *Genes Dev* 8:1888-1896 (1994).
- Stein et al., *J Biol Chem* 271:23588-23593 (1996)
- Stein et al., *Genes Dev* 12:667-678 (1998).
- Steward et al., "Solid Phase Peptide Synthesis", W. H. Freeman Co.,  
San Francisco, (1969).
- 10 Szybalska et al., *Proc Natl Acad Sci USA* 48:2026 (1962).
- Takahashi et al., *Kidney Int* 53:826-835 (1998).
- Thomas et al., *J Biol Chem* 269:19953-19962 (1994).
- Thorpe et al., *Cancer Res* 47:5924-5931 (1987).
- Tsiotra et al., *J Biol Chem* 271:29216-29222 (1996).
- 15 U.S. Pat. No. 4,244,946
- U.S. Pat. No. 4,215,051
- U.S. Pat. No. 4,340,535
- U.S. Pat. No. 4,472,509
- U.S. Pat. No. 5,660,827
- 20 U.S. Pat. No. 5,733,876
- U.S. Pat. No. 5,753,230
- U.S. Pat. No. 5,762,918
- U.S. Pat. No. 5,766,591
- U.S. Pat. No. 5,776,427

Vaickus et al., *Cancer Invest* 9:195-209 (1991).

Van Heeke et al., *J Biol Chem* 264:5503-5509 (1989).

Vogel & Muller-Eberhard, *Anal. Biochem* 118(2):262-268 (1981).

Wallner et al., *Microsc Res Tech* 39:261-284 (1997).

5 Wang, Y. and Pallen, C.J., *J Biol Chem* 267:16696-16702 (1992).

Weiss, A. and Schlessinger, J., *Cell* 94:277-280 (1998).

Wigler et al., *Cell* 11:223 (1977).

WO 84/03564

10 Zimmer et al., *Peptides* (1992) pp. 393-394, ESCOM Science Publishers,  
B.V., (1993).

Zola, *Monoclonal Antibodies: a Manual of Techniques*, CRC Press, Inc. (1987).

It will be understood that various details of the invention can be changed  
without departing from the scope of the invention. Furthermore, the foregoing  
description is for the purpose of illustration only, and not for the purpose of  
15 limitation--the invention being defined by the claims.

CLAIMS

What is claimed is:

1. A purified antibody which preferentially binds an EC RTP/DEP-1, or a fragment or derivative of the antibody.
- 5 2. The antibody of claim 1, which preferentially binds an ectodomain of the EC RTP/DEP-1.
3. The antibody of claim 2, which preferentially binds an eight amino acid epitope having the sequence QSRDTEVL, or an eight amino acid epitope having an analog sequence of the sequence QSRDTEVL, of the EC RTP/DEP-10 1 ectodomain.
4. The antibody of claim 1, which is a monoclonal antibody, or fragment or derivative thereof.
5. The antibody of claim 4, which is monoclonal antibody EC RTPAb-1, having a molecular weight of about 150 kDa and which preferentially binds15 to an ectodomain of the EC RTP/DEP-1.
6. The antibody of claim 4, further characterized as having the immunoreaction characteristics of a monoclonal antibody produced by a hybridoma cell line having ATCC accession number HB12570.
7. The antibody of claim 6, where the monoclonal antibody is a20 monoclonal antibody produced by a hybridoma cell line having ATCC accession number HB12570.
8. The antibody of claim 1, wherein the antibody is humanized.
9. The antibody of claim 8, which preferentially binds to an ectodomain of the EC RTP/DEP-1.

10. The antibody of claim 9, which preferentially binds an eight amino acid epitope having the sequence QSRDTEVL, or an eight amino acid epitope having an analog sequence of the sequence QSRDTEVL, of the EC RTP/DEP-1 ectodomain.

5 11. The antibody of claim 8, wherein the humanized antibody comprises monoclonal antibody EC RTPAb-1, having a molecular weight of about 150 kDa and which preferentially binds to an ectodomain of the EC RTP/DEP-1.

10 12. The antibody of claim 8, wherein the humanized antibody is further characterized as having the immunoreaction characteristics of a monoclonal antibody produced by a hybridoma cell line having ATCC accession number HB12570.

15 13. The antibody of claim 12, where the monoclonal antibody is monoclonal antibody produced by a hybridoma cell line having ATCC accession number HB12570.

14. The antibody of claim 1, in a pharmaceutically acceptable diluent or excipient.

20 15. A pharmaceutical composition comprising an isolated and purified biologically active EC RTP/DEP-1 polypeptide, or amide, conjugated, cyclized, fragment, chemically modified embodiment thereof, and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition of claim 15, wherein the polypeptide further comprises an ectodomain of the EC RTP/DEP-1.

17. The pharmaceutical composition of claim 16, wherein the polypeptide further comprises an eight amino acid epitope of the ectodomain of the EC RTP/DEP-1, the epitope having the sequence QSRDTEVL, or an eight amino acid epitope of the ectodomain of the EC RTP/DEP-1 having an analog of the sequence QSRDTEVL.

18. The pharmaceutical composition of claim 15, further comprising a cell expressing the EC RTP/DEP-1 polypeptide.

19. A method of screening a candidate substance for an ability to modulate a receptor tyrosine phosphatase, the method comprising:

- 10 (a) establishing a test sample comprising a receptor tyrosine phosphatase;
- (b) administering a candidate substance to the test sample; and
- (c) measuring a receptor tyrosine phosphatase biological activity in the test sample;
- 15 (d) detecting phosphotyrosine residues on the receptor tyrosine phosphatase; and
- (e) determining that the candidate substance modulates the receptor tyrosine phosphatase if the receptor tyrosine phosphatase biological activity measured for the test sample is greater or less than the receptor tyrosine phosphatase biological activity measured for a control sample and if the amount of phosphotyrosine residues on the receptor tyrosine phosphatase is greater or less than an amount of phosphotyrosine residues on a receptor tyrosine phosphate derived from a control sample.

20. The method of claim 19, wherein the test and control samples further comprise a cell, and the receptor tyrosine phosphatase is expressed in the cell.

21. The method of claim 20, wherein the test and control sample  
5 comprise cells expressing an EC RTP/DEP-1.

22. The method of claim 21, wherein the EC RTP/DEP-1 activity is selected from the group consisting of modulation of endothelial cell migration and proliferation, modulation of density induced growth arrest, modulation of angiogenesis and combinations thereof.

10 23. The method of claim 19, wherein the candidate substance further comprises a cell or cell lysate comprising a natural ligand for the receptor tyrosine phosphatase, and the method further comprises isolating the natural ligand for the receptor tyrosine phosphatase.

24. The method of claim 23, wherein the receptor tyrosine  
15 phosphatase comprises the EC RTP/DEP-1.

25. The method of claim 24, wherein the ligand is isolated by lysing the cells and passing the cell lysate over a column containing the EC RTP/DEP-1 bound to a solid phase matrix within the column.

26. The method of claim 24, wherein the ligand is isolated by  
20 constructing a cDNA library from the cells binding the ligand; transfecting the cDNA library into a cell line that does not exhibit binding of the ligand; screening the cell line for newly acquired specific binding; isolating DNA from cells exhibiting specific binding; and sequencing the isolated DNA to determine the DNA sequence for the ligand.

27. A recombinant cell line suitable for use in the assay of claim 19.

28. A method of screening a candidate substance for an ability to modulate EC RTP/DEP-1 biological activity, the method comprising:

- 5
- (a) establishing a test sample comprising an EC RTP/DEP-1 polypeptide or fragment thereof;
  - (b) administering a candidate substance to the test sample; and
  - (c) measuring an interaction, effect, or combination thereof, of the candidate substance on the test sample to thereby determine the ability of the candidate substance to modulate EC RTP/DEP-1
- 10 biological activity.

29. The method of claim 28, wherein the test sample further comprises a cell expressing EC RTP/DEP-1, and wherein the step of measuring an interaction, effect, or combination thereof, of the candidate substance on the test sample further comprises:

- 15
- (i) comparing the interaction, effect, or combination thereof, of the candidate substance on the test sample with the interaction, effect, or combination thereof, of the candidate substance on a cell not expressing EC RTP/DEP-1; and
  - (ii) determining that candidate compound modulates EC RTP/DEP-1
- 20 activity by demonstrate a lack of interaction, effect or combination thereof, of the candidate compound on cells not expressing EC RTP/DEP-1.

30. The method of claim 28, wherein said step of measuring an interaction, effect, or combination thereof, of the candidate substance on the



test sample further comprises measuring binding between the candidate substance and the test sample by:

- 5 (i) contacting the candidate substance with an EC RTP/DEP-1 polypeptide or fragment thereof under conditions favorable to binding the candidate with an EC RTP/DEP-1 polypeptide or fragment thereof to form a complex therebetween; and

- (ii) detecting the complex.

31. The method of claim 30, wherein the complex is detected via a label conjugated to the EC RTP/DEP-1 polypeptide or fragment thereof; via a  
10 labeled reagent that specifically binds to the complex subsequent to its formation; or via a competition assay with a substance known to bind the EC RTP/DEP-1 polypeptide for fragment thereof.

32. The method of claim 30, wherein the EC RTP/DEP-1 polypeptide or fragment thereof is conjugated with a detectable label.

15 33. The method of claim 32, wherein the step of detecting the complex further comprises:

- (i) separating the complex from unbound labeled EC RTP/DEP-1 polypeptide or fragment thereof; and  
(ii) detecting the detectable label which is present in the complex or  
20 which is unbound.

34. The method of claim 30, wherein the EC RTP/DEP-1 polypeptide fragment is a EC RTP/DEP-1 ectodomain fragment.

35. The method of claim 34, wherein the EC RTP/DEP-1 ectodomain fragment comprises an eight amino acid epitope having the sequence n-QSRDTEVL-c.

36. The method of claim 30, wherein the candidate substance is an antibody, or derivative or fragment thereof.

37. The method of claim 36, wherein the candidate antibody, or derivative or fragment thereof, is derived from a recombinant phage-displayed antibody library.

38. A kit for use screening a candidate substance for an ability to modulate EC RTP/DEP-1 biological activity, the kit comprising a EC RTP/DEP-1 ectodomain polypeptide, or fragment thereof, contained in a first container.

39. The kit of claim 38, wherein the EC RTP/DEP-1 ectodomain polypeptide, or fragment thereof, comprises an eight amino acid epitope having the sequence n-QSRDTEVL-c.

40. The kit of claim 38, further comprising a solid phase support.

41. The kit of claim 40, where the EC RTP/DEP-1 ectodomain polypeptide, or fragment thereof, is immobilized to the solid phase support.

42. The kit of claim 38, further comprising a detectable label.

43. The kit of claim 41, wherein the detectable label is contained in another container or wherein EC RTP/DEP-1 ectodomain polypeptide, or fragment thereof, comprises the detectable label.

44. The kit of claim 43, wherein the detectable label is a radioactive label or an enzyme.

Abstract of the Disclosure

A method of modulating angiogenesis in a vertebrate subject, the method comprising administering to the vertebrate subject an EC RTP/DEP-1 activity-modulating amount of a composition, whereby an EC RTP/DEP-1 within  
5 the vertebrate subject is contacted by the composition; and modulating angiogenesis through the contacting of the EC RTP/DEP-1 with the composition. Optionally, the composition includes a monoclonal antibody which preferentially binds EC RTP/DEP-1. Methods for screening for modulators of EC RTP/DEP-1 are also disclosed.




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 2A



FIG. 2B




FIG. 2C



FIG. 2D



FIG. 2E

Artery



FIG. 3A



FIG. 3C



FIG. 3E

Glomerulus



FIG. 3B



FIG. 3D



FIG. 3F



FIG. 4A



FIG. 4B




FIG. 4C




FIG. 4D




FIG. 5A




FIG. 5B






FIG. 6A





FIG. 6B



**FIG. 7**




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 9B




FIG. 9A




FIG. 9C




FIG. 10



FIG. 11




FIG. 12



FIG. 13A







FIG. 13B



Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)  
Approved for use through 9/30/00. OMB 0651-0032  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)</b>		<b>Attorney Docket Number</b>	
		<b>First Named Inventor</b>	Daniel, Thomas O.
		<b>COMPLETE IF KNOWN</b>	
		<b>Application Number</b>	
		<b>Filing Date</b>	
		<b>Group Art Unit</b>	
		<b>Examiner Name</b>	

☒ Declaration Submitted with Initial Filing      OR      ☐ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**MODULATION OF ENDOTHELIAL CELL SURFACE RECEPTOR  
ACTIVITY IN THE REGULATION OF ANGIOGENESIS**

the specification of which (Title of the Invention)

☒ is attached hereto  
OR

☐ was filed on (MM/DD/YYYY) [ ] as United States Application Number or PCT International

Application Number [ ] and was amended on (MM/DD/YYYY) [ ] (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 356(b) of any foreign application(s) for patent or inventor's certificate, or 356(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	
		<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

**Burden Hour Statement:** This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/01 (12-87)  
Approved for use through 9/30/00. OMB 0651-0032  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
09/152,160	September 10, 1998	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02C attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

<input type="checkbox"/> Customer Number <span style="border: 1px solid black; display: inline-block; width: 150px; height: 1.2em; vertical-align: middle;"></span> OR <input checked="" type="checkbox"/> Registered practitioner(s) name/registration number listed below	Place Customer Number Bar Code Label here
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------

Name	Registration Number	Name	Registration Number
Richard E. Jenkins	28,428	Arles A. Taylor, Jr.	39,395
Jeffrey L. Wilson	36,058	David P. Gloekler	41,037
Jennifer L. Skord	30,687	Gregory A. Hunt	41,085

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label  OR ☒ Correspondence address below

Name	Richard E. Jenkins, JENKINS & WILSON, P.A.				
Address	Suite 1400 University Tower				
Address	3100 Tower Boulevard				
City	Durham	State	NC	ZIP	27707
Country	USA	Telephone	001-919-493-8000	Fax	001-919-419-0383

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:		<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle (if any))			Family Name or Surname		
Thomas O.			Daniel		
Inventor's Signature					Date
Residence: City	Nashville	State	TN	Country	US
Post Office Address	3905B Trimble Road				
Post Office Address					
City	Nashville	State	TN	ZIP	37215
				Country	USA
<input checked="" type="checkbox"/> Additional inventors are being named on the <u>1</u> supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto					

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (3-97)  
Approved for use through 9/30/98. OMB 0651-0032  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION

**ADDITIONAL INVENTOR(S)**  
**Supplemental Sheet**  
Page 1 of 1

<b>Name of Additional Joint Inventor, if any:</b>		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any))				Family Name or Surname			
Takamune				Takahashi			
Inventor's Signature						Date	
Residence: City	Nashville	State	TN	Country	US	Citizenship	Japan
Post Office Address		2025 Woodmont Boulevard					
Post Office Address		Apt. 335					
City	Nashville	State	TN	ZIP	37215	Country	USA
<b>Name of Additional Joint Inventor, if any:</b>		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any))				Family Name or Surname			
Raymond				Mernaugh			
Inventor's Signature						Date	
Residence: City	Nashville	State	TN	Country	US	Citizenship	US
Post Office Address							
Post Office Address							
City		State		ZIP		Country	
<b>Name of Additional Joint Inventor, if any:</b>		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any))				Family Name or Surname			
Inventor's Signature						Date	
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		ZIP		Country	

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.